Neurologische Klinik und Poliklinik
Refine
Has Fulltext
- yes (524)
Year of publication
Document Type
- Journal article (356)
- Doctoral Thesis (165)
- Report (2)
- Book (1)
Keywords
- ischemic stroke (27)
- multiple sclerosis (22)
- Parkinson's disease (19)
- deep brain stimulation (19)
- Parkinson’s disease (18)
- neuroinflammation (18)
- Fabry disease (17)
- Multiple Sklerose (17)
- stroke (17)
- Schlaganfall (16)
- neuropathic pain (15)
- Polyneuropathie (14)
- inflammation (13)
- Medizin (12)
- Parkinson-Krankheit (12)
- pain (12)
- Neuropathie (10)
- subthalamic nucleus (10)
- neuropathy (9)
- Schmerz (8)
- biomarker (8)
- dopamine (8)
- dystonia (8)
- neurology (8)
- Charcot-Marie-Tooth (7)
- cytokines (7)
- macrophages (7)
- mouse model (7)
- neurodegeneration (7)
- skin biopsy (7)
- small fiber neuropathy (7)
- B cells (6)
- Fabry-Krankheit (6)
- Hautbiopsie (6)
- MS (6)
- Makrophage (6)
- Maus (6)
- Neurodegeneration (6)
- Neuropathischer Schmerz (6)
- Pain (6)
- Parkinson (6)
- acute ischemic stroke (6)
- antibodies (6)
- autoantibodies (6)
- depression (6)
- fibromyalgia syndrome (6)
- Autoantikörper (5)
- B7-H1 (5)
- Biomarker (5)
- Dystonie (5)
- EAE (5)
- Entzündung (5)
- Fibromyalgie (5)
- Immunsystem (5)
- MRI (5)
- Makrophagen (5)
- Neurofascin (5)
- Parkinson disease (5)
- Ranvier-Schnürring (5)
- basal ganglia (5)
- blood-brain barrier (5)
- gene expression (5)
- magnetic resonance imaging (5)
- middle cerebral artery occlusion (5)
- movement disorders (5)
- neuroprotection (5)
- polyneuropathy (5)
- skin punch biopsy (5)
- traumatic brain injury (5)
- tremor (5)
- walking (5)
- ALS (4)
- CCI (4)
- Charcot-Marie-Syndrom (4)
- Cytokines (4)
- GFAP (4)
- Myelin (4)
- Nervenfaser (4)
- Neuroinflammation (4)
- Neuronale Plastizität (4)
- Neuropathy (4)
- Propriozeption (4)
- Puppenhandillusion (4)
- T-Lymphozyt (4)
- blood–brain barrier (4)
- cervical dystonia (4)
- corneal confocal microscopy (4)
- disease (4)
- factor XII (4)
- fibromyalgia (4)
- gait initiation (4)
- immunohistochemistry (4)
- inflammasome (4)
- macrophage (4)
- mechanical thrombectomy (4)
- mice (4)
- microRNA (4)
- motor learning (4)
- mutation (4)
- myelin (4)
- platelets (4)
- regulatory T cells (4)
- thrombo-inflammation (4)
- Autoantibodies (3)
- Biopsie (3)
- Blut-Hirn-Schranke (3)
- CMT (3)
- COVID-19 (3)
- Carotisstenose (3)
- Caspr (3)
- Chemokine (3)
- DYT1 (3)
- ELISPOT (3)
- Entmarkung (3)
- Fabry (3)
- Fabry-associated pain (3)
- Gehirn (3)
- Genexpression (3)
- Guillain-Barré-Syndrom (3)
- HBMEC (3)
- Inflammation (3)
- Langerhans cells (3)
- Macrophage (3)
- Mausmodell (3)
- Mice (3)
- Multiple sclerosis (3)
- NLRP3 (3)
- Natalizumab (3)
- Nervendegeneration (3)
- Neuralgie (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- PNP (3)
- Peripheres Nervensystem (3)
- Rehabilitation (3)
- Synuclein <alpha-> (3)
- T cells (3)
- T-lymphocytes (3)
- Ultraschalldiagnostik (3)
- Ureaplasma parvum (3)
- Zytokine (3)
- adaptive immune system (3)
- aging (3)
- animal models (3)
- anxiety (3)
- autoantibody (3)
- biomarkers (3)
- brain (3)
- cerebellar tDCS (3)
- cerebral ischemia (3)
- children (3)
- chronic pain (3)
- closed head injury (3)
- cognitive impairment (3)
- complement (3)
- criteria (3)
- degeneration (3)
- dementia (3)
- enzyme replacement therapy (3)
- essential tremor (3)
- experimental autoimmune encephalomyelitis (3)
- experimental stroke (3)
- expression (3)
- gait analysis (3)
- genetics (3)
- heart failure (3)
- immune cells (3)
- immune system (3)
- kinematics (3)
- length of stenosis (3)
- local field potentials (3)
- lymphocytes (3)
- meningitis (3)
- mesencephalic locomotor region (3)
- miRNA (3)
- microglia (3)
- neurofascin (3)
- neurofilament light chain (3)
- neuroimmunology (3)
- neuropathischer Schmerz (3)
- neutrophils (3)
- photothrombotic stroke (3)
- quality of life (3)
- rehabilitation (3)
- rubber hand illusion (3)
- stroke unit (3)
- tMCAO (3)
- therapy (3)
- thrombolysis (3)
- tight junctions (3)
- transcranial magnetic stimulation (3)
- transplantation (3)
- trial (3)
- AQP4 (2)
- Acetylcholinrezeptor (2)
- Altern (2)
- Alzheimer’s disease (2)
- Antikörper (2)
- Arteria carotis interna (2)
- B-lymphocytes (2)
- BDNF (2)
- Basalganglien (2)
- CIDP (2)
- CNS (2)
- CSF-1 (2)
- Cerebrospinal fluid (2)
- Charcot-Marie-Tooth disease (2)
- Cortactin (2)
- Crush (2)
- Cytokine (2)
- Degeneration (2)
- Diabetes mellitus (2)
- Diagnosis (2)
- Dystonia (2)
- Elektrophysiologie (2)
- Encephalopathia hepatica (2)
- Enzyme replacement therapy (2)
- Evoziertes Potenzial (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fc-receptor (2)
- Fibromyalgia (2)
- Fibromyalgia syndrome (2)
- Glatiramer acetate (2)
- Guillain-Barre-Syndrome (2)
- Guillain-Barré syndrome (2)
- HLA-G (2)
- Haut (2)
- Hautstanzbiopsie (2)
- IENFD (2)
- Ischemic stroke (2)
- Komplement (2)
- Körperselbstgefühl (2)
- Körperwahrnehmung (2)
- LTD (2)
- Langzeitdepression (2)
- Lewy-like pathology (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- MBP (2)
- MCC950 (2)
- MCP-1 (2)
- Mechanisms (2)
- Meningitis (2)
- Microglia (2)
- Morbus Fabry (2)
- Motorisches Lernen (2)
- Multiple Sclerosis (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- NEUROWIND (2)
- NMOSD (2)
- NMR-Tomographie (2)
- NOAC (2)
- Nervenbiopsie (2)
- Neuroimmunologie (2)
- Neuronal ceroid lipofuscinosis (2)
- Nucleus subthalamicus (2)
- Outcome survey (2)
- PET (2)
- Peripheral nervous system (2)
- Proprioception (2)
- Quantitative sensorische Testung (2)
- Schwann cell (2)
- Schwann-Zelle (2)
- Serotonin (2)
- Small fiber Neuropathie (2)
- Small fiber neuropathy (2)
- Spinalganglion (2)
- Stroke (2)
- Stroke unit (2)
- T lymphocytes (2)
- T-Lymphozyten (2)
- TDMT (2)
- Tiermodell (2)
- Tourette syndrome (2)
- Transkranielle magnetische Stimulation (2)
- Treatment (2)
- TrkB (2)
- Ultraschall (2)
- Ureaplasma urealyticum (2)
- Zentralnervensystem (2)
- accuracy (2)
- alpha-synuclein (2)
- amyotrophic-lateral-sclerosis (2)
- animal model (2)
- anticoagulation (2)
- atrial fibrillation (2)
- autoimmune (2)
- autoimmunity (2)
- axonal damage (2)
- axonaler Schaden (2)
- balance (2)
- base of support (2)
- beta oscillations (2)
- binding (2)
- biopsy (2)
- blood brain barrier (2)
- blood flow (2)
- blood pressure (2)
- blood-brain-barrier (2)
- c-Fos (2)
- caregiver burden (2)
- carotid atherosclerosis (2)
- carotid stenosis (2)
- carotid ultrasound (2)
- case report (2)
- central nervous system (2)
- cerebral autoregulation (2)
- cerebrospinal fluid (2)
- cerebrovascular disorders (2)
- chemokines (2)
- chronic cerebrovascular disease (2)
- chronic kidney disease (2)
- colony-stimulating factor (2)
- consolidation (2)
- contact-kinin system (2)
- contactin (2)
- cytokine (2)
- degree of stenosis (2)
- demyelination (2)
- diabetic neuropathy (2)
- diagnosis (2)
- diagnostic markers (2)
- differential diagnosis (2)
- dimethyl fumarate (2)
- disability (2)
- diseases of the nervous system (2)
- echocardiography (2)
- edema (2)
- electrophysiology (2)
- endoglin (2)
- endothelial cells (2)
- exercise (2)
- freezing of gait (2)
- gait (2)
- gene (2)
- generalized cerebral edema (2)
- glial fate modulation (2)
- glial fibrillary acidic protein (2)
- globotriaosylceramide (2)
- glycine receptor (2)
- glycoprotein receptor Ib (2)
- guidelines (2)
- hearing loss (2)
- hypoxia (2)
- immunomodulation (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- infarction (2)
- inflammatory neuropathy (2)
- ion channels (2)
- ischemic penumbra (2)
- just noticeable difference (JND) (2)
- lesions (2)
- leukocytes (2)
- locomotor adaptation (2)
- locus coeruleus (2)
- machine learning (2)
- major depression (2)
- miR-21 (2)
- miRNS (2)
- mitochondria (2)
- mortality (2)
- motor control (2)
- mouse models (2)
- multiple system atrophy (2)
- multiple-sclerosis (2)
- musical syntax (2)
- nerve biopsy (2)
- nerve fibers (2)
- nerve fibres (2)
- neurological disorders (2)
- neuronal plasticity (2)
- neurons (2)
- neuroscience (2)
- node of Ranvier (2)
- opioids (2)
- outcomes (2)
- pain questionnaire (2)
- pain-related evoked potentials (2)
- parkinson's disease (2)
- passive transfer (2)
- pathogenesis (2)
- peripheral blood mononuclear cells (2)
- peripheral nervous system (2)
- peripheral neuropathy (2)
- photothrombosis (2)
- physical activity (2)
- preclinical research (2)
- predictive value (2)
- prognosis (2)
- protein (2)
- psychophysics (2)
- quantitative sensory testing (2)
- randomized controlled trial (2)
- rat (2)
- relapse (2)
- renal system (2)
- resting tremor (2)
- reversible posterior leukoencephalopathy syndrome (2)
- second hit (2)
- small fiber pathology (2)
- spinal cord (2)
- spinal cord injury (2)
- split-belt treadmill (2)
- striatum (2)
- stroke care (2)
- synaptic vesicles (2)
- systems biology (2)
- tDCS (2)
- telemedicine (2)
- thrombosis (2)
- time perception (2)
- transient ischemic attack (2)
- transient middle cerebral artery occlusion (2)
- ultrasound (2)
- velocity (2)
- voluntary movement (2)
- von Willebrand factor (2)
- α-synuclein (2)
- (Para-)nodale Autoantikörper (1)
- 2B (1)
- 3D fluoroscopy (1)
- 3D structure (1)
- 3D-Struktur (1)
- 5-Dihydroxycinnamat (1)
- 5-HIAA (1)
- 5-HTT Knock Out (1)
- 5-dihydroxycinnamate (1)
- 5IA-SPECT (1)
- 65-kda isoform (1)
- A delta-Faser (1)
- A-delta fibers (1)
- A53T (1)
- A53T mutation (1)
- A53T-Mutation (1)
- ACE (1)
- ADHD (1)
- ALS mimic (1)
- ALS treatment (1)
- ALSIN gene (1)
- APERIO (1)
- APERIO Hybrid (1)
- AQP (1)
- ASC (1)
- ASIC 3 (1)
- ATF3 (1)
- Abciximab (1)
- Adaptive cell transfer (1)
- Adaptives Immunsystem (1)
- Adaptorproteine (1)
- Adult patients (1)
- Affekt (1)
- Agalsidase beta (1)
- Agalsidase beta therapy (1)
- Agaphelin (1)
- Age (1)
- Agrin (1)
- Alemtuzumab (1)
- Alkoholische Polyneuropathie (1)
- Allodynie (1)
- Alpha galactosidase (1)
- Alpha-Synuclein (1)
- Alter (1)
- Alzheimer disease (1)
- Alzheimer’s dementia (1)
- Amitriptylin (1)
- Amplitude (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- Aneurysma (1)
- Animal models (1)
- Anosognosie (1)
- Anti-Neurofascin-Autoantikörper-assoziierten Neuropathie (1)
- Antibody index (1)
- Antigen CD8 (1)
- Antikoagulation (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Apoptosis (1)
- Approved immunomodulators (1)
- Aquaporin 4 (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Aquaporin4 (1)
- Arteria cerebri media (1)
- Arterial Diameters (1)
- Arterial water (1)
- Asomatognosie (1)
- Ataxia (1)
- Atrial fibrillation (1)
- Atrophie (1)
- Autoantigen (1)
- Autoimmun (1)
- Autoimmunität (1)
- Autophagie (1)
- Autophagie <Physiologie> (1)
- Axon (1)
- Axon degeneration (1)
- Axonal degeneration (1)
- Azathioprine (1)
- Aδ- and C-fibers (1)
- B-Lymphocyten (1)
- BB/OKL rats (1)
- BCI (1)
- Barkhof criteria (1)
- Barthel Index (1)
- Barthel-Index modified Rankin-Scale (1)
- Barthel-Index modifizierte Rankin-Skala (1)
- Basal Ganglia (1)
- Basal ganglia (1)
- Beam-Walking-Test (1)
- Beta-glucocerebrosidase (1)
- Bewegungsstörung (1)
- Bildgebung (1)
- Biopsiediagnostik von entzündlichen Polyneuropathien (1)
- Blutgerinnungsfaktor XII (1)
- Borrelien (1)
- Borreliose (1)
- Borreliosis (1)
- Braak (1)
- Brain (1)
- Brain atrophy (1)
- Brain edema (1)
- Brain ischemia (1)
- Brain-derived neurotrophic factor (1)
- Brainstem encephalitis (1)
- C-Faser (1)
- C-reactive protein (1)
- C.376A>G (p.S126G) (1)
- C1-inhibitor (1)
- C57BL/6 mice (1)
- CAS (1)
- CCL2 (1)
- CCS (1)
- CD105 (1)
- CD133 (1)
- CD19 (1)
- CD52 (1)
- CEA (1)
- CLN3 (1)
- CMV (1)
- CNS Myelination (1)
- CNS disease (1)
- CNS imaging (1)
- CNS integrity (1)
- COMPLEX 1 (1)
- COU254 (1)
- CRM (1)
- CRPS (1)
- CSF (1)
- CSF-1 Rezeptor (1)
- CSF-1 Rezeptor Inhibitor (1)
- CSF-1 receptor (1)
- CSF-1 receptor inhibitor (1)
- CSF-1-Rezeptor-Inhibitor (1)
- CSVD (1)
- CXCL10 (1)
- CXCL4 (1)
- CXCL5 (1)
- CXCL7 (1)
- CXCL8 (1)
- CXCR2 (1)
- Ca2+ homeostasis (1)
- Ca2+ ion analysis (1)
- Ca2+ leak (1)
- Ca2+ oscillation (1)
- Campylobacter jejuni (1)
- Capsaicin (1)
- Capsaicin receptor (1)
- Carotis (1)
- Carotischirurgie (1)
- Caspase (1)
- Caspr1 (1)
- Cell Index (1)
- Cell therapy (1)
- Cell-based assays (1)
- Central Nervous System (1)
- Cerebellitis (1)
- Cerebral blood flow (1)
- Cerebral small vessel disease (1)
- Cerebral vasospasm (1)
- Cerebral-ischemia (1)
- Cgrin (1)
- Charcot-Marie-Tooth Neuropathie (1)
- Charcot-Marie-Tooth Neuropathy (1)
- Charcot-Marie-Tooth syndrom (1)
- Charcot-Marie-Tooth-Hoffmann-Syndrom (1)
- Charcot–Marie–Tooth disease (1)
- Charcot–Marie–Tooth disease type 1A (1)
- Chemokine Receptor (1)
- Chemokinrezeptors (1)
- CholinomiRs (1)
- Chronic Constriction Injury (1)
- Chronic heart failure (1)
- Chronic neuropathic pain (1)
- Chronische Niereninsuffizienz (1)
- Chronischer Schmerz (1)
- Cisterna magna (1)
- Clinical manifestations (1)
- Clinically silent stroke (1)
- Coefficient (1)
- Cognitive behavior (1)
- Cognitive decline (1)
- Cold (1)
- Computertomographie (1)
- Connexin32 deficient mice (1)
- Connexin32-defiziente Maus (1)
- Consortium to Establish a Registry for Alzheimer's Disease (1)
- Contactin (1)
- Contactin 1 (1)
- Corneal confocal microscopy (1)
- Corneale confocale Mikroskopie (1)
- Cortico-striatal projection neurons (1)
- Crespi effect (1)
- Cyclophosphamid (1)
- Cyclophosphamide (1)
- D313Y genotype (1)
- DARPA (1)
- DBS biomarkers (1)
- DBS programming (1)
- DOPA-responsive-dystonia (1)
- DRD1 (1)
- DYT-TOR1A (1)
- Deep Brain Stimulation (1)
- Deeskalation (1)
- Deeskalationstherapie (1)
- Deflazacort (1)
- Dekompressionskraniektomie (1)
- Delphi procedure (1)
- Demenz (1)
- Demyelinating peripheral neuropathy (1)
- Demyelination (1)
- Demyelinisierung (1)
- Dendritische Zelle (1)
- Denervierung (1)
- Devic Maus (1)
- Devic mice (1)
- Devic’s syndrome (1)
- Diabetic polyneuropathy (1)
- Diabetische Neuropathie (1)
- Diabetische Polyneuropathie (1)
- Dialyse (1)
- Diapedese (1)
- Dimethylfumarat (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Disease (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Dorsal Root Ganglion (1)
- Dorsal root ganglion (1)
- Dose reduction (1)
- Double hemorrhage model (1)
- Drosophila (1)
- Duchenne dystrphy (1)
- Durchblutung (1)
- Dyskinesie (1)
- EAAT2 (1)
- ECM (1)
- EEG (1)
- EEG data (1)
- EMG (1)
- ER Ca2+ imaging (1)
- ER Ca2+ store (1)
- ERK1/2 (1)
- ERT (1)
- ET (1)
- Edema (1)
- Effekte von Contactin-1-IgG-Patientenantikörpern im Zellkulturmodell (1)
- El Escorial (1)
- Electrophysiology (1)
- Embryonalentwicklung (1)
- Emotionales Verhalten (1)
- Encephalitis (1)
- Endarteriektomie (1)
- Endothelzelle (1)
- English version (1)
- Entzündungsreaktion (1)
- Entzündungsschmerz (1)
- Enzephalitis (1)
- Epilepsy (1)
- Epitop (1)
- Erbliche Neuropathien (1)
- Ereigniskorreliertes Potenzial (1)
- Erregbarkeit (1)
- Escalation therapy (1)
- Eskalationstherapie (1)
- Essentieller Tremor (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Evoked potentials (1)
- Evozierte Potenziale (1)
- Experimental stroke (1)
- Experimentaltumor (1)
- Experimenteller Schlaganfall (1)
- Expression (1)
- F-18-FDG PET (1)
- FOSMN (1)
- FOXP3 (1)
- FP-CIT SPECT (1)
- FSHD (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Fabry pain (1)
- Fabry’s disease (1)
- Facial nerve palsy (1)
- Facioscapulohumeral muscular dystrophy (1)
- Factor messenger-RNA (1)
- Fatigue (1)
- Fc-Rezeptor (1)
- Fibroblasten (1)
- Fibroblasts (1)
- Fluoreszenz (1)
- Fluoreszenzmikroskopie (1)
- Focal dystonie (1)
- Frabin/Fgd4 (1)
- Funktionelle Kernspintomografie (1)
- GABAergic neurons (1)
- GAP 43 (1)
- GCH1 (1)
- GFAP-astrocytopathies (1)
- GLA KO mouse model (1)
- GP-IIb/IIIa-Antagonist (1)
- GP-IIb/IIIa-antagonist (1)
- GPCR (1)
- GRAID (1)
- Gait initiation (1)
- Gedächtnis (1)
- Gefäßverschluss (1)
- Gehirn-Computer-Schnittstelle (1)
- Gene-expression (1)
- Genetik (1)
- Genmutation (1)
- Geriatrics (1)
- Geriatrie (1)
- Geste (1)
- Gland (1)
- Glial fibrillary acidic protein (1)
- Glioblastoma (1)
- Glioma stem cells (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barr'e-Syndrom (1)
- Guillain-Barré Syndrom (1)
- HMGB1 (1)
- HMSN (1)
- HMSN immune cells (1)
- HPF (1)
- HRUS (1)
- Hautzelle (1)
- Head-injury (1)
- Hearing loss (1)
- Heat Hyperalgesia (1)
- Hemodynamic depression (1)
- Heparin (1)
- Hepatische Enzephalopathie (1)
- Hereditary spastic paraplegia (1)
- Hereditäre Neuropathien (1)
- Hereditäre spastische Spinalparalyse (1)
- Hereditäre spastsiche Paraplegie (1)
- Heriditary sensor and motor neuropathy (1)
- Heriditäre sensomotorische Neuropathie (1)
- Herpesvirus 6 (1)
- Hirnblutung (1)
- Hirndruck (1)
- Hirnstimulation (1)
- Hirnödem (1)
- Hornhaut (1)
- Hyperalgesia (1)
- Hyperalgesie (1)
- IBA-1 (1)
- ICB (1)
- ICH (1)
- IL-15 (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- IPND criteria (1)
- IVIG (1)
- IVIg (1)
- Identification (1)
- Idiopathisches Parkinson-Syndrom (1)
- IgG (1)
- IgG4 (1)
- Ih (1)
- Imaging (1)
- Immune cells (1)
- Immune system (1)
- Immunfluoreszenz (1)
- Immunmodulation (1)
- Immunoblot (1)
- Immunreaktion (1)
- Immunzellen (1)
- Impfung (1)
- Improvement (1)
- Infarkt (1)
- Infections (1)
- Inflamamtion (1)
- Influenza (1)
- Infrarotspektroskopie (1)
- Inherited neuropathies (1)
- Innervation (1)
- Insulin (1)
- Integrin (1)
- Integrin alpha-4 (1)
- IntelliCage (1)
- Interferon <beta-> (1)
- Interferon beta (1)
- Interleukin-18 (1)
- Interleukin-4 (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intraepidermale Nervenfaserdichte (1)
- Intrathekale Applikation (1)
- Intravascular coagulation (1)
- Intrinsische Gerinnungskaskade (1)
- Ischemia (1)
- Ischämischer Schlaganfall (1)
- Ixolaris (1)
- JCV (1)
- K+ channel (1)
- K2P channels (1)
- KCNK5 (1)
- K\(_{2P}\)5.1 (1)
- Kaliumkanal (1)
- Kallikrein-Kinin-System (1)
- Kleinfaserneuropathie (1)
- Kleinfaseruntersuchungen (1)
- Kleinhirn (1)
- Knochentumor (1)
- Ko-inhibitorischer Signalweg (1)
- Kognition (1)
- Kognition bei mHE (1)
- Komplement <Immunologie> (1)
- Komplementsystem (1)
- Konfokale Mikroskopie (1)
- Konsolidierung (1)
- Kontrastmittel (1)
- Kopfschemata (1)
- Kortikobasales Syndrom (1)
- Kostimulation (1)
- Kreuzreaktivität (1)
- Kritische Flimmerfrequenz (1)
- L-DOPA (1)
- LI-rTMS (1)
- LIMP-2 (1)
- LSVT-big therapy (1)
- LVO (1)
- Ladder-Rung-Walking-Test (1)
- Laktat (1)
- Landouzy-Déjerine-Atrophie (1)
- Langzeitpotenzierung (1)
- Latenzänderung (1)
- Lebensqualität bei mHE (1)
- Lebensqualität nach stroke (1)
- Leukemia Inhibitory Factor (1)
- Lewy-Pathologie (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Liquor cerebrospinalis (1)
- Lokale Feldpotentialaktivität (1)
- Long COVID (1)
- Longitudinally extensive transverse myelitis (1)
- Lyme-Krankheit (1)
- Lyme-disease (1)
- Lymphozyten (1)
- Lymphozyten mediierter Angriff auf Neurone (1)
- Lysosomal storage disease (1)
- Ländliche Klinik (1)
- M-CSF (1)
- M. Fabry (1)
- M.Fabry (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMN (1)
- MMP9 (1)
- MOC fibers (1)
- MOG (1)
- MOG-IgG (1)
- MPZ (P0) (1)
- MRI criteria (1)
- MRI lesion study (1)
- MRT (1)
- MRT-Läsionsstudie (1)
- MSSS (1)
- Macrophages (1)
- Magnetic resonance imaging (1)
- Magnetic-resonance (1)
- Matched pairs (1)
- McDonald criteria (1)
- Mediated Inflammatory Hyperalgesia (1)
- Medium spiny neurons (1)
- Meige syndrome (1)
- Memory dysfunction (1)
- Meningoencephalitis (1)
- Meningoenzephalitis (1)
- Merkel cell density (1)
- Merkel cells (1)
- Merkelzelle (1)
- Mesencephal Locomotor Region (1)
- Mesenchymal stem/stromal cells (1)
- Mesenzephale Lokomotor Region (1)
- Methotrexate (1)
- Methyl-2 (1)
- Methylmalonsäure (1)
- Microarray (1)
- Middle cerebral artery infarction (1)
- Migräne (1)
- Mikroblutung (1)
- Mikroglia (1)
- Mikroglobulin <beta-2-> (1)
- Mikroneurographie (1)
- Mitoxantron (1)
- Miyoshi myopathy (1)
- Model (1)
- Molecular-weight heparin (1)
- Mononeuropathie (1)
- Monopolar depression (1)
- Morbus Parkinson (1)
- Morphologie <Biologie> (1)
- Motoneuron (1)
- Motoneuronen (1)
- Motor Control (1)
- Motor cortex (1)
- Motor learning (1)
- Motor nerve biopsy (1)
- Motor plasticity (1)
- Motoradaptation (1)
- Motorische Endplatte (1)
- Motorkonsolidierung (1)
- Mucopolysaccharidosis IIIa (1)
- Multiple Sclerosis Society of Canada (1)
- Multiplen Sklerose (1)
- Multisensorische Integration (1)
- Musikwahrnehmung (1)
- Muskel (1)
- Muskelhypertonie (1)
- Muster (1)
- Myasthenia gravis (1)
- Myatrophische Lateralsklerose (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelinopathie (1)
- Myelinopathy (1)
- Myelinprotein (1)
- Myelitis (1)
- Myeloma (1)
- Myoblast (1)
- Myoblasten (1)
- Myopathie (1)
- Mysthenia Gravis (1)
- NADPH oxidase inhibitors (1)
- NAP-2 (1)
- NETs (1)
- NF-\(\kappa\)B (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NLG (1)
- NMO (1)
- NMO-IGG (1)
- NPC1 gene (1)
- NPC2 gene (1)
- NPSI (1)
- NaV1.9 (1)
- Nahinfrarot-Spektroskopie (1)
- Natriumkanal (1)
- Nav1.8 (1)
- Nav1.9 (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Nervenregeneration (1)
- Nervenregeneration ; Periphere Nervenverletzung ; Neuromuskuläre Krankheit ; Axonverletzung ; Entmarkung (1)
- Nervensonographie (1)
- Nervenultraschall (1)
- Nestin (1)
- Neuroborreliose (1)
- Neurodegenerative Erkrankung (1)
- Neurofascin-155-IgG4-(Para-)nodopathie (1)
- Neurofascin-155-IgM (1)
- Neurofeedback (1)
- Neurogenic inflammation (1)
- Neurogeriatrie (1)
- Neurologie (1)
- Neuromyelitis Optica (1)
- Neuromyelitis optica (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neuronale Ceroid Lipofuszinose (1)
- Neuropathic Pain (1)
- Neuroplastizität (1)
- Neuropsychologie (1)
- Neuropsychologischer Test (1)
- Neuroregeneration (1)
- Neurotrophe Faktoren (1)
- Neurotrophic Factors (1)
- Neurotrophic factors (1)
- Neurotrophine (1)
- Neutralisation <Chemie> (1)
- Neutrophil (1)
- NfL (1)
- Nicht-motorische Begleitsymptome (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Niederfrequenzstimulation (1)
- Niemann–Pick disease type C (1)
- Nociceptor (1)
- Nodo-parandopathy (1)
- Nozizeptor (1)
- OCB (1)
- ON-Freezing (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Opioidrezeptor (1)
- Optical coherence tomography (1)
- Optikusnervenscheidendurchmesser (1)
- Orai2 (1)
- Oral anticoagulation (1)
- Osteopontin (1)
- Outcome (1)
- P300 Welle (1)
- PD-1 (1)
- PD-L1 (1)
- PF4 (1)
- PHES (1)
- PI3K isoforms (1)
- PML (1)
- PMP22 (1)
- PPAR-gamme (1)
- PREP (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Pan-Neurofascin-IgG3 (1)
- Paradoxical heat sensation (1)
- Paranodale und nodale Autoantikörper (1)
- Paranodopathie (1)
- Parkinson Krankheit (1)
- Parkinson's Disease (1)
- Parkinsons disease (1)
- Parkionson's disease (1)
- Partial Sciatic Transection (1)
- Passiv-Transfer (1)
- Pathomechanismus (1)
- Pathophysiologie (1)
- Patient Reported Outcome (1)
- Pedunculopontiner tegmentaler Nukleus (1)
- Perfusion (1)
- Peripheral Inflammation (1)
- Periphere Nerven (1)
- Periphere mononukleäre Zellen (1)
- Pharmacological management (1)
- Phosphodiesterasehemmer (1)
- Photothrombotic Stroke (1)
- Physiotherapie (1)
- Pilzkörper (1)
- Plasma extravasation (1)
- Plasmakallikrein (1)
- Plasmakallikrein ischämischer Schlaganfall (1)
- Plastizität (1)
- Platelets (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Pointing error (1)
- Polyneuropathy (1)
- Pregnancy (1)
- Procalcitonin (1)
- Prodigy (1)
- Prognose (1)
- Prognostik (1)
- Progressive supranuclear palsy (1)
- Proton Magnetic Resonance Spectroscopy (1)
- Protonen (1)
- Protonenspektroskopie (1)
- Psychologische Diagnostik (1)
- Psychophysik (1)
- QSART (1)
- QST (1)
- Quality of life (1)
- Quantitativ Sensorische Testung (1)
- Quantitative Sensorische Testung (1)
- Quantitativer sudomotorischer Axonreflextest (1)
- R-715 (1)
- RAG-1 (1)
- RECK (1)
- RKIP (1)
- RNA extraction (1)
- RT-PCR (1)
- Randomized controlled trial (1)
- Randomized controlled-trial (1)
- Ranvier'sche Schnürringe (1)
- Rasmussen-Syndrom (1)
- Rat (1)
- Rat Sensory Neurons (1)
- Rats (1)
- Ratte (1)
- Raumwahrnehmung (1)
- Receptors (1)
- Regeneration (1)
- Regenerative medicine (1)
- Regulatorische T-Zellen (1)
- Regulatory T cells (1)
- Resilienz (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Revaskularisierung (1)
- Rheumatoid-Arthritis (1)
- Rho-GTPase Cdc42 (1)
- Rhombencephalitis (1)
- Rhythmusperzeption (1)
- Richardson-Olszewski-Syndrome (1)
- Rituximab (1)
- Rochester diabetic neuropathy (1)
- SARS-CoV (1)
- SB332235 (1)
- SERCA (1)
- SGLT2 inhibitors (1)
- SHRSP (1)
- SMA (1)
- SNI (1)
- SOD1 mutations (1)
- SPECT (1)
- SPG17 (1)
- SPG4 (1)
- SREBP (1)
- STAIR (1)
- STDT (1)
- STEMI (1)
- Sars-CoV-2 (1)
- Schlaganfall-Netzwerk (1)
- Schmerz-assoziierte elektrisch evozierte Potentiale (1)
- Schmerz-assoziierte evozierte Potenziale (1)
- Schmerzerfassung (1)
- Schmerzforschung (1)
- Schmerzfragebogen (1)
- Schmerzzeichnungen (1)
- Schreibkrampf (1)
- Schub (1)
- Schwann Zellen (1)
- Schwann cell dedifferentiation (1)
- Schwann cell differentiation (1)
- Schwann cells (1)
- Schwann-cells (1)
- Schwann´sche Zelle (1)
- Schweißdrüse (1)
- Schädel-Hirn-Trauma (1)
- Score (1)
- Screening questionnaire (1)
- Secondary stroke prevention (1)
- Sekundärprävention (1)
- Sensitivity (1)
- Sensorik <Neurophysiologie> (1)
- Serotonin-Reuptake-Hemmer (1)
- Sigaltransduktionsweg (1)
- Signaltransduktion (1)
- Silver-syndrome (1)
- Sjorgens-syndrome (1)
- Skelettmuskel (1)
- Skin biopsy (1)
- Small Fiber Neuropathie (1)
- Small fiber dysfunction (1)
- Small-fiber neuropathy (1)
- Sonic hedgehog (1)
- Sonographie (1)
- Sphingosine 1-Phosphate (1)
- Spinalganglienneuron (1)
- Stammganglienblutung (1)
- Stenosis degree (1)
- Stenosis length (1)
- Stent (1)
- Stereologie (1)
- Stiff-Person-Syndrom (1)
- Stim (1)
- Stimuli (1)
- Striatum (1)
- Stroke Manager (1)
- Stroke-Unit (1)
- Subarachnoid (1)
- Subarachnoid hemorrhage (1)
- Subarachnoidalblutung (1)
- Suralisbiopsien (1)
- Suralisneurographie (1)
- Survey (1)
- Synapse (1)
- Synaptic plasticity (1)
- System involvement (1)
- T cell activation (1)
- T cell line (1)
- T lymphocyte (1)
- T- Lymphozyt (1)
- T-PA (1)
- T-cell epitope (1)
- T-cell repertoire (1)
- T-cells (1)
- T-lymphocyte (1)
- T-zell epitope (1)
- T-zell repertoir (1)
- TAP Alertness (1)
- TASK2 (1)
- TBI (1)
- TIMP-1 (1)
- TIND (1)
- TLO (1)
- TMS (1)
- TNF (1)
- TNF alpha (1)
- TNF-R1 (1)
- TNF-R2 (1)
- TNF-Rezeptor-1 (1)
- TNF-Rezeptor-2 (1)
- TNF-receptor-1 (1)
- TNF-receptor-2 (1)
- TNF-receptors (1)
- TNF-α (1)
- TNFα (1)
- TOR1A (1)
- TRP (1)
- TRP Channels (1)
- TRPV 1 (1)
- TSPO (1)
- Tdp-43 (1)
- Telemedizin (1)
- Temporal Discrimination Threshold (1)
- Therapy (1)
- Thermal Hyperalgesia (1)
- Thrombektomie (1)
- Thrombo-inflammation (1)
- Thromboinflammation (1)
- Thrombolyse (1)
- Thrombozyt (1)
- Thrombus (1)
- Thrombus formation (1)
- Thymom (1)
- Tiefe Hirnstimulation (1)
- Topiramat (1)
- Topiramate (1)
- Tor1a (1)
- Torticollis (1)
- Training (1)
- Transkranielle Magnetstimulation (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Trauma (1)
- Trem2 (1)
- Trepanation (1)
- Triamcinolon (1)
- Trick (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tuberkulose (1)
- Tumor-Nekrose-Faktor (1)
- Tumor-Nekrose-Faktor <alpha> (1)
- Tumor-Nekrose-Faktor <alpha>-Inhibitor (1)
- Type 1 diabetes (1)
- Umfragestudie (1)
- Ureaplasma species (1)
- Urämie (1)
- VCAM (1)
- VCAM-1 (1)
- VR1 (1)
- Vaccination (1)
- Vascular system (1)
- Vaskulitische Polyneuropathie (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Venlafaxin (1)
- Verbesserung (1)
- Vergleich (1)
- ViMS (1)
- Viral (1)
- Virus (1)
- Visuomotorisches Lernen (1)
- Vitamin D (1)
- Vitamin D-Mangel (1)
- Vitamin-B12-Mangel (1)
- Volon A (1)
- Von-Willebrand-factor (1)
- Western blot (1)
- White matter lesions (1)
- Wiederbelebung (1)
- Wingerchuk criteria 2006 and 2015 (1)
- Wissenschaftlicher Nachwuchs (1)
- Würzburg / Universität Würzburg (1)
- X-Chromosom (1)
- X-Inaktivierung (1)
- X-chromosomal inactivation (1)
- XAV-939 (1)
- ZNS (1)
- Zeitwahrnehmung (1)
- Zellkultur (1)
- Zentralnervensystems (1)
- Zonula Occludens-1 (1)
- Zytokin (1)
- [18F]FDG positron emission tomography (1)
- abciximab (1)
- acid sphingomyelinase (1)
- activation (1)
- activity-dependent slowing (1)
- acute lymphoblastic leukaemia (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adhesion molecules (1)
- adrenal medulla (1)
- adsorption (1)
- adult-onset (1)
- advanced therapy medicinal products (1)
- afferents (1)
- age (1)
- aggression (1)
- agrin (1)
- albumin (1)
- algorithm (1)
- alias pilot trial (1)
- allodynia (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha-galactosidase A (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amitriptyline (1)
- amygdala (1)
- amyloidosis (1)
- amyotrophe Lateralsklerose (1)
- amyotrophic lateral sclerosis (1)
- amyotrophic lateral sclerosis (ALS) (1)
- analgesia (1)
- analgesic medication (1)
- aneurysm surgery (1)
- angiography (1)
- animal behavior (1)
- ankles (1)
- anodic stimulation (1)
- antagomir (1)
- anthropometric measurement (1)
- anthropometric measurements (1)
- anti-Amphiphysin Antikörper (1)
- anti-amphiphysin antibodies (1)
- anti-aquaporin-4 antibody (1)
- anti-contactin-1 (1)
- antibody (1)
- anticoagulants (1)
- antidepressants (1)
- antigen-presenting cells (1)
- antithrombotic (1)
- apoE (1)
- apoe (1)
- apomorphine (1)
- apoplexy (1)
- aquaporin 4 (1)
- aquaporin-4 autoantibodies (1)
- areas (1)
- arm (1)
- artery occlusion (1)
- asomatognosia (1)
- assistive devices (1)
- association (1)
- association studies in genetics (1)
- assoziative Paarstimulation (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrophy Kennedys-disease (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attenuation of disease (1)
- atypical chemokine receptor 3 (1)
- auditorisches Neurofeedback Training (1)
- auditory (1)
- autoantibody (aAb) (1)
- autoantigen (1)
- autoimmune encephalitis (1)
- autoimmune neuroinflammation (1)
- autoimmune nodopathy (1)
- autoimmunität (1)
- autophagy (1)
- autoradiography (1)
- axon growth (1)
- axon guidance molecules (1)
- axonal degeneration (1)
- axonal integrity (1)
- axonal transcriptome (1)
- axonal transport (1)
- axonopathic changes (1)
- back pain (1)
- barrier (1)
- barrier integrity (1)
- basal forebrain cholinergic neurons (1)
- basal ganglia hemorrhage (1)
- behavioral disorders (1)
- beta oscillation (1)
- beta power (1)
- beta2 Mikroglobulin knock-out Mäuse (1)
- beta2 microglobulin knock-out mice (1)
- bilateral internal carotid artery stenosis (1)
- bilateral motor network (1)
- binding analysis (1)
- biological locomotion (1)
- biopsies (1)
- blood (1)
- blood CSF barrier (1)
- blood coagulability (1)
- blood coagulation (1)
- blood nerve barrier (1)
- blood sedimentation (1)
- body diagram (1)
- body ownership (1)
- bone (1)
- bone-marrow (1)
- botulinum neurotoxin (1)
- botulinum toxin (1)
- bradykinesia (1)
- bradykinin (1)
- brain dynamics (1)
- brain edema (1)
- brain endothelium (1)
- brain metabolic alterations (1)
- brain networks (1)
- brain state (1)
- brain stem (1)
- burning pain (1)
- bystander activation (1)
- c-fibre (1)
- calpain (1)
- capsaicin (1)
- cardiac imaging (1)
- cardiac magnetic resonance imaging (1)
- cardiovascular disease (1)
- care (1)
- care tempis (1)
- caregiver (1)
- caudate nucleus (1)
- celiac disease (1)
- cell adhesion (1)
- cell binding assay (1)
- cellular therapy (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- cerebral arteries (1)
- cerebral blood flow (1)
- cerebral endothelial cell (1)
- cerebral endothelial cells (1)
- cerebral inflammation (1)
- cerebral microbleeds (1)
- cerebral small vessel disease (1)
- cerebrale Ischämie (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- chitinase-3-like protein 1 (1)
- choline acetyltransferase (1)
- cholinergic activity (1)
- cholinergic system (1)
- chronic constriction nerve injury (1)
- chronic constriction nerve injury (CCI) (1)
- chronic heart failure (1)
- chronic inflammatory demyelinating polyneuropathy (1)
- chronic stimulation (1)
- chronic stress (1)
- chronische Multiple Sklerose (1)
- circuitopathies (1)
- classification (1)
- claudin-1 (1)
- clinical approach (1)
- clinical diagnosis (1)
- clinical neurology (1)
- clinical outcome (1)
- clinical phenotype (1)
- clip control (1)
- closed-loop (1)
- cluster analysis (1)
- co-inhibitory signalling (1)
- coagulation (1)
- coagulation factor XIIa (1)
- cochlea (1)
- cognitive (1)
- cognitive decline (1)
- cognitive function (1)
- coherence (1)
- coherence analysis (1)
- collagens (1)
- collateral circulation (1)
- colony stimulating factor 1 (1)
- compensatory strategies (1)
- complement deposition (1)
- complex regional pain syndrome (1)
- comprehension (1)
- computed tomography (1)
- computer vision (1)
- computerized tomography (1)
- contact activation system (1)
- contactin-associated protein 1 (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- contrast-enhanced MRI (1)
- contrastmedium (1)
- conversion (1)
- coordination (1)
- coping (1)
- corneale confocale Mikroskopie (1)
- cortical activation (1)
- cortical excitability (1)
- cortical oscillatory activity (1)
- cortical pathology (1)
- cortical silent period (1)
- cortico-striatal synapse (1)
- corticobasal syndrome (1)
- costimulation (1)
- critical flimmer frequency (1)
- crossover trial (1)
- crush (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- dSPN (1)
- dSTORM (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- data filtering (1)
- decompressive hemicraniectomy (1)
- decreasing autonomy (1)
- deep brain stimulation (DBS) (1)
- deep brain-stimulation (1)
- dekompressive Hemikraniektomie (1)
- delayed cerebral infarction (1)
- delays progression (1)
- demography (1)
- demyelinating disease (1)
- demyelinating polyneuropathy (1)
- demyelinating polyradiculoneuropathy (1)
- dendric cells (1)
- dendritic cells (1)
- dendritische Zellen (1)
- dermal B cells (1)
- design (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diagnostic medicine (1)
- diagnostics (1)
- diapedesis (1)
- diffuse (1)
- digital medicine (1)
- direct pathway (1)
- directional deep brain stimulation (1)
- disease model (1)
- disease progression (1)
- disease severity (1)
- disease-modifying therapy (1)
- disorder (1)
- domain potassium channels (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- dopaminergic cells (1)
- dorsal root ganglion neuron (1)
- drug (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- early-onset isolated dystonia (1)
- edoxaban (1)
- effects (1)
- efficacy (1)
- ejection fraction (1)
- elderly (1)
- electroencephalography (1)
- electromyography (1)
- element (1)
- embolic stroke (1)
- emergency care (1)
- emotion (1)
- emulsions (1)
- encephalitis (1)
- endothelin-1 (1)
- endotheliopathy (1)
- enteropathy (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- epitope (1)
- etanercept (1)
- event-related desynchronization (1)
- evoked potentials (1)
- excitability (1)
- exome sequencing (1)
- experimental (1)
- experimental autoimmune neuritis (1)
- experimental design (1)
- expert opinion (1)
- extensiv transverse myelitis (1)
- extracellular domain (1)
- eye movement disorders (1)
- fMRI Analyse (1)
- facial pain (1)
- factor XI (1)
- familial amyloidotic polyneuropathy (1)
- family caregiver (1)
- fatigue (1)
- fear (1)
- fear memory (1)
- feasibility (1)
- feeling of bodily self (1)
- female Fabry patients (1)
- females (1)
- fetal (1)
- fibers (1)
- fibroblast (1)
- fibromyalgia sydrome (1)
- fine-mapping (1)
- finger-tapping task (1)
- finger-tapping task (FTT) (1)
- fingolimod (1)
- flotillin-1 lipid rafts (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- fokale Dystonie (1)
- fosfomycin (1)
- fractionator (1)
- free radical scavenger (1)
- freezing of gait (FOG) (1)
- fullerenes (1)
- functional MRI (1)
- functional connectivity (1)
- functional neuroanatomy (1)
- functional status (1)
- fungal infection (1)
- future directions (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait modulation (1)
- gait-phase prediction (1)
- galactomannan (1)
- gender (1)
- gene mutations (1)
- gene variant (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- gene-environmental interaction (1)
- generalized cerebellar atrophy (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- geste (1)
- giant cell arteritis (1)
- glia (1)
- glial damage (1)
- glioblastoma multiforme (1)
- globus pallidus (1)
- globus pallidus pars interna (GPi) (1)
- glucocerebrosidase mutation (1)
- glycation end products (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ibα (1)
- glycosylation (1)
- granzyme B (1)
- gridle muscular-dystrophy (1)
- growth (1)
- growth pattern (1)
- gustatory dysfunction (1)
- health behavior (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hemicraniectomy (1)
- hemoglobin (1)
- hemorrhagic transformation (1)
- heparin (1)
- hereditary motor and sensory neuropathy (1)
- hereditary neuropathy (1)
- hereditary spastic paraplegia (1)
- hereditary spastic paraplegia (HSP) (1)
- hereditäre Neuropathien (1)
- hereditäre periphere Neuropathie (1)
- hereditäre sensomotorische Neuropathie (1)
- hernia repair (1)
- hexanucleotide repeat (1)
- high contrast (1)
- hip (1)
- hippocampus (1)
- histology (1)
- homotypic fusion and protein sorting (1)
- hospitals (1)
- human (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human muscle-cells (1)
- human neurons (1)
- humans (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hyperekplexia (1)
- hypothermia (1)
- hypoxic-ischemic encephalopathy (1)
- hypoxische Enzephalopathie (1)
- i.v. thrombolysis (1)
- iNOS-Synthase (1)
- iPSC (1)
- idiopathic inflammatory myopathies (1)
- image quality (1)
- image-guided programming (1)
- imaging (1)
- immaturity (1)
- immune (1)
- immune-response (1)
- immunisation (1)
- immunofluorescence (1)
- immunofluoreszenz (1)
- immunoglobulin-G (1)
- immunzellen (1)
- implants (1)
- in-vivo (1)
- incidence (1)
- increased risk (1)
- induced neural stem cells (1)
- inducible expression (1)
- inducible nitric oxide synthase (1)
- inebilizumab (1)
- inertial measurement units (1)
- infantile neuronal ceroid lipofuscinosis (1)
- infarction size (1)
- infarction volume (1)
- infection (1)
- inflammatory cascades (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory pain (1)
- informal care (1)
- informal caregiving (1)
- informed consent (1)
- inherited metabolic disorders (1)
- inherited peripheral neuropathy (1)
- injection site reactions; (1)
- innate immune system (1)
- innervation (1)
- integrin α2 (1)
- integrins (1)
- intensity of attention (1)
- interference (1)
- interleukin-1 receptor antagonist (1)
- interleukin-8 (1)
- internal carotid artery stenosis (1)
- internal globus pallidus (1)
- internal medicine (1)
- internet-based intervention (1)
- interval timing (1)
- interview (1)
- intra-limb anticipatory postural adjustments (1)
- intracerebral hemorrhage (1)
- intracranial bleeding (1)
- intracranial hemorrhage (1)
- intractable hiccup (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intraoperative (1)
- intrathecal (1)
- intrathecal application (1)
- intrathekal (1)
- intravenous immunoglobulin (1)
- intravenous thrombolysis (1)
- invasive electric stimulation (1)
- ipsilateral motor evoked potential (1)
- ipsilateral motor network (1)
- iron (1)
- iron dyshomeostasis (1)
- iron oxide nanoparticles (1)
- ischemia (1)
- ischemia/reperfusion injury (1)
- ischemic cascade (1)
- kallikrein-kinin system (1)
- kallikrein–kinin system (1)
- kinesthesia (1)
- kinin receptor (1)
- kinin receptors (1)
- kleinkalibrige Nervenfasern (1)
- knees (1)
- knockout (1)
- large vessel occlusion (1)
- latency shift (1)
- learning (1)
- levodopa (1)
- levodopa-induced dyskinesia (1)
- linkage (1)
- liponeurocytoma (1)
- locomotion (1)
- locomotor network (1)
- long-term pain (1)
- longitudinally extensive transverse myelitis (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal dysfunction (1)
- lysosomal enzyme (1)
- lysosomal storage disease (1)
- lyso‐Gb3 (1)
- mRNA expression (1)
- magnesium (1)
- makrophagen (1)
- malignant middle cerebrial artery infarction (1)
- maligner Mediainfarkt (1)
- management (1)
- mast cells (1)
- matrix metalloproteinases (1)
- mechanical energy (1)
- mechanisms (1)
- medial ganglionic eminence (1)
- medication therapy failure (1)
- medikamentöse Sekundärprävention bei stroke (1)
- medulloblastoma (1)
- memory (1)
- meningoencephalitis (1)
- mental health (1)
- mental rotation (1)
- mesenchymal stem and stromal cells (1)
- mesenchymal stem cells (1)
- metaanalysis (1)
- methylphenidate (1)
- miR-182-5p (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- mice impact (1)
- microangiopathy (1)
- microscopy (1)
- microsphere/macrosphere (1)
- microtubules (1)
- midbrain (1)
- migraine (1)
- migraineur (1)
- minimal hepatische Enzephalopathie (1)
- minocycline (1)
- mixed fiber neuropathy (1)
- mixed methods (1)
- molecular biology (1)
- molecular mechanism (1)
- molecular mimicry (1)
- molecular signature (1)
- monocycline (1)
- monocytes (1)
- monomethyl fumarate (1)
- morphology (1)
- motoneuron (1)
- motoneuron disease (1)
- motor (1)
- motor axonal neuropathy (1)
- motor cortex (1)
- motor evoked potential (MEP) (1)
- motor function (1)
- motor neuron disease (1)
- motor neuropathy (1)
- motor proteins (1)
- motor-evoked potentials (MEP) (1)
- motorisches Lernen (1)
- mouse (1)
- mouse brain microvascular endothelial cell cultur (1)
- movement (1)
- movement disorder (1)
- movements (1)
- multiple sklerosis (1)
- multisensorische Integration (1)
- multisensory integration (1)
- muscle atrophy (1)
- muscle strength (1)
- mushroom-body (1)
- musikalische Syntax (1)
- musk myasthenia gravis (1)
- myasthenia gravis (1)
- myelin biology and repair (1)
- myelin protein zero (1)
- myelination (1)
- myoblast (1)
- myocardial infarction (1)
- myopathy (1)
- nACh-Rezeptor (1)
- natalizumab (1)
- natural history (1)
- natural killer cells (1)
- near infrared spectroscopy (1)
- near-infrared spectroscopy (1)
- neonatal meningitis (1)
- nerve conduction studies (1)
- nerve tumor (1)
- nerve-fibers (1)
- nervous system (1)
- nervous-system (1)
- neural apoptosis (1)
- neural biomarkers (1)
- neural stem cell (1)
- neural stem cells (1)
- neuralgia (1)
- neurobehavioural deficits (1)
- neuroborreliosis (1)
- neurocritical care (1)
- neurocytoma (1)
- neurofilaments (1)
- neurogen (1)
- neuroleukemiosis (1)
- neurological (1)
- neurological complications (1)
- neurological examination (1)
- neuromelanin (1)
- neuromuskuläre Endplatte (1)
- neuronal apoptosis (1)
- neuronal ceroid lipofuscinosis (1)
- neuronal differentiation (1)
- neuronal network (1)
- neuronal stem cells (1)
- neurone (1)
- neuronopathy (1)
- neurophysiology (1)
- neuroplasticity (1)
- neuropsychology (1)
- neuroregeneration (1)
- neurorepair (1)
- neurotrophins (1)
- neutralization (1)
- neutrophil (1)
- nicotinamide (1)
- nicotinic receptors (1)
- nociceptive Schwann cells (1)
- nociceptor sensitization (1)
- node of ranvier (1)
- nodes of Ranvier (1)
- non-motor features (1)
- nonalcoholic steatohepatitis (1)
- noradrenalin (1)
- noradrenaline (1)
- norepinephrine (1)
- novo renal transplantation (1)
- nucleus ventralis intermedius (1)
- nystagmus (1)
- object recognition memory (1)
- obstacle avoidance (1)
- occlusion (1)
- olfactory dysfunction (1)
- olfactory testing (1)
- oligodendroglia (1)
- on-site examination (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- opioidreceptor (1)
- optic nerve sheath diameter (1)
- optic neuritis (1)
- optical coherence tomography (1)
- orofacial pain (1)
- orofazialer Schmerz (1)
- oscillations (1)
- outcome (1)
- outer hair cell (OHC) (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- p38 mitogen-activated protein kinase (1)
- p57kip2 (1)
- pain drawings (1)
- pain pattern (1)
- pain related evoked potentials (1)
- pain sensation (1)
- pain-associated behavior (1)
- paired associative stimulation (1)
- pallidal stimulation (1)
- pandemic (1)
- paranode (1)
- paranodopathy (1)
- paraparesis (1)
- parkinson disease (1)
- parkinsons disease (1)
- passiv transfer (1)
- pathology section (1)
- pathophysilogical mechanisms (1)
- pathophysiology (1)
- pathway analysis (1)
- pathways (1)
- patient reported outcome measures (1)
- patient triage (1)
- pattern (1)
- pedunculopontine nucleus (PPN) (1)
- pegylated insulin-like growth factor 1 (1)
- peptide (1)
- periperal nerve (1)
- peripheral injury (1)
- peripheral nerve (1)
- peripheral nerve injury (1)
- peripheral nerve involvement (1)
- peripheral nerve trauma (1)
- peripheral nerves (1)
- peripheral nervous-system (1)
- permanent and transient middle cerebral artery occlusion (1)
- pet (1)
- ph (1)
- pharmacology (1)
- phosphodiesterase inhibitor (1)
- phosphorylated tau protein (1)
- physical therapy modalities (1)
- physiology (1)
- pilot project (1)
- placebo-controlled (1)
- plaque cross-sectional area (1)
- plasma extravasation (1)
- plasma oxysterols (1)
- plasminogen (1)
- plasticity (1)
- platelet activation (1)
- platelet aggregation (1)
- pleasant touch (1)
- point-of-care echocardiography (1)
- pointing task (1)
- polymorphism (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- population-based (1)
- position estimation (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- postherpetic neuralgia (1)
- postural control (1)
- posture (1)
- potassium channels (1)
- potent inducer (1)
- precision medicine (1)
- predictive coding (1)
- prednisone (1)
- prefrontal cortex (1)
- premotor cortex (1)
- presynaptic inhibition (1)
- preterm birth (1)
- preventive treatment (1)
- procalcitonin (1)
- progression (1)
- progressive ataxia (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- progressive multiple sclerosis (1)
- progressive supranuclear palsy (1)
- proinflammatory cytokine (1)
- protein and mRNA expression (1)
- proteins (1)
- proteolipid protein (1)
- proteolipid protein gene (1)
- proteomics (1)
- protons (1)
- prä-post Design (1)
- prämotorischer Cortex (1)
- psychiatric disorders (1)
- psychological support (1)
- psychosocial resilience (1)
- purmorphamine (1)
- putamen (1)
- quality (1)
- quality control (1)
- quality of life (QoL) (1)
- quality-control (1)
- qutenza (1)
- randomized controlled double-blind study (1)
- rasmussen encephalitis (1)
- rat brain microvascular endothelial cell culture (1)
- rat hepatocytes (1)
- rats (1)
- reach-to-grasp movement (1)
- reaction-time tasks (1)
- receptor (1)
- receptor tyrosine kinase (1)
- recombinant tissue-type plasminogen activator (1)
- recommendations (1)
- recovery (1)
- recurrence (1)
- reflex (1)
- regeneration (1)
- regional heterogeneity (1)
- regulation (1)
- regulatorische T Zellen (1)
- regulatory cells (1)
- reinnervation (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- religiosity (1)
- renal function (1)
- reoxygenation (1)
- reperfusion (1)
- reperfusion injury (1)
- reproducible outcome measure (1)
- reserpinized rat model (1)
- resilience (1)
- responsivity (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- retrograde Marker (1)
- retrograde tracers (1)
- rett (1)
- rhythm perception (1)
- rhythmperception (1)
- risk (1)
- risk factors (1)
- risk of fall (1)
- rt-PA (1)
- rural clinics (1)
- rutabaga (1)
- safety and tolerability (1)
- scale (1)
- schmerz-assoziierte elektrisch-evozierte Potenziale (1)
- sciatic nerve (1)
- sciatic nerve injury (1)
- sciatic nerves (1)
- search filter (1)
- secondary infarct growth (1)
- secretome (1)
- segmental centers of mass (1)
- sensomotorisch (1)
- sensory (1)
- sensory neurons (1)
- seronegative (1)
- seropositive (1)
- serotonin (1)
- serotonin transporter (1)
- serum (1)
- sex addiction (1)
- shedding (1)
- shingles (1)
- siRNA (1)
- signal peptide (1)
- signal transduction pathway (1)
- simulation training (1)
- single photon emission computed tomography (SPECT) (1)
- skewed (1)
- skilled forelimb movements (1)
- skin cells (1)
- skin diseases (1)
- skin tumors (1)
- small fiber tests (1)
- small molecule (1)
- small nerve fibers (1)
- small nerve fibres (1)
- small vessel disease (1)
- small-fiber neuropathy (1)
- small-fiber-Neuropathie (1)
- small-molecule Inhibitoren (1)
- small-molecule inhibitors (1)
- socioeconomic status (1)
- software (1)
- soleus muscles (1)
- soluble endoglin (1)
- somatic resilience (1)
- somatosensory temporal discrimination (1)
- somatosensory-evoked-potentials (1)
- spannungsgesteuerter Natriumkanal (1)
- spatial attention (1)
- sphingolipids (1)
- spinal muscular atrophy (1)
- spinal-cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stenosis (1)
- stent-retriever device (1)
- steroids (1)
- stiff-person syndrome (SPS) (1)
- stimulation (1)
- stimulationsinduzierte Plasitzität (1)
- store-operated Ca2+ entry (1)
- stress (1)
- striatal dopaminergic dysregulation (1)
- stroke management (1)
- stroke networks (1)
- stromal cells (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous injection (1)
- substance-P (1)
- subthalamic nucleus (STN) (1)
- sural nerve (1)
- survey (1)
- swimming (1)
- switch (1)
- symptom control (1)
- symptom-specific treatment (1)
- synapse (1)
- synaptic plasticity (1)
- synaptic transmission (1)
- syndrome (1)
- system (1)
- systematic review (1)
- systemic inflammation (1)
- systolic dysfunction (1)
- target considerations (1)
- task retention (1)
- telemedicine network (1)
- temporal discrimination threshold (1)
- teriflunomide (1)
- term follow-up (1)
- tetrahydroisoquinoline derivates (1)
- tetraparesis (1)
- threshold discrimination identification test (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombolysis (tPA) (1)
- thrombus formation (1)
- thymoma (1)
- tics (1)
- tiefe Hirnstimulation (1)
- time (1)
- timing (1)
- tissue resident T cells (1)
- tissue-plasminogen activator (1)
- tnf (1)
- tolerance (1)
- toleranz (1)
- tool (1)
- topography (1)
- torsinA (1)
- torticollis (1)
- transcranial direct current stimulation (1)
- transcranial magnetic simulation (TMS) (1)
- transgenic mouse model (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion model (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- transkranielle Gleichstromstimulation (tDCS) (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- transmission electron microscopy (1)
- treatment options (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- treatment-resistant depression (1)
- triamcinolone acetonide (1)
- trick (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- troponin (1)
- tuberculous meningitis (1)
- tumor (1)
- tumor immunity (1)
- tumor necrosis factor-α (1)
- ultrasound imaging (1)
- under-dosing (1)
- up-regulation (1)
- upper limb (1)
- validation (1)
- variants of unknown significance (1)
- vascular cell adhesion molecule-1 (1)
- vascular dementia (1)
- vascular homeostasis (1)
- vascular permeability (1)
- vasculopathy (1)
- venlafaxine (1)
- versus (1)
- vertebrobasilar insufficiency (1)
- vertebrobasilar stroke (1)
- vertigo (1)
- vessel patency (1)
- vestibular (1)
- videooculography (1)
- virtual reality (1)
- visual activity (1)
- visual pathways (1)
- visuoadaptive motor task (1)
- visuomotorisches Lernen (1)
- volume regulation (1)
- vs (1)
- weight drop (1)
- white blood cells (1)
- white matter disease (1)
- white matter hyperintensities (1)
- white matter lesions (1)
- zeitliche Wahrnehmungsschwellen (1)
- zerebelläre Gleichstromstimulation (1)
- zerebrale Endothelzelle (1)
- zerebrale Endothelzellen (1)
- Ältere (1)
- α-Galactosidase A (1)
- α-Synuclein (1)
- α-synuclein-specific T cells (1)
- α‐GalA 3D‐structure (1)
- β-APP (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (524)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (26)
- Graduate School of Life Sciences (19)
- Neurochirurgische Klinik und Poliklinik (18)
- Medizinische Klinik und Poliklinik I (17)
- Institut für Klinische Epidemiologie und Biometrie (16)
- Institut für Klinische Neurobiologie (16)
- Rudolf-Virchow-Zentrum (16)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (14)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (13)
Schriftenreihe
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Institut für Musikphysiologie und Musiker-Medizin der Hochschule für Musik, Theater und Medien, Hannover (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- KfH Nierenzentrum (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Politecnico di Milano (1)
- Sahin Lab, F.M. Kirby Neurobiology Center Boston Children’s Hospital, Department of Neurology, Harvard Medical School (1)
- Wurzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Wurzburg, Germany (1)
- Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), University of Würzburg, Würzburg, Germany (1)
Efficacy of transcranial direct current stimulation in people with multiple sclerosis: a review
(2022)
Background and purpose
Multiple sclerosis (MS) is a chronic inflammatory disease causing a wide range of symptoms including motor and cognitive impairment, fatigue and pain. Over the last two decades, non-invasive brain stimulation, especially transcranial direct current stimulation (tDCS), has increasingly been used to modulate brain function in various physiological and pathological conditions. However, its experimental applications for people with MS were noted only as recently as 2010 and have been growing since then. The efficacy for use in people with MS remains questionable with the results of existing studies being largely conflicting. Hence, the aim of this review is to paint a picture of the current state of tDCS in MS research grounded on studies applying tDCS that have been done to date.
Methods
A keyword search was performed to retrieve articles from the earliest article identified until 14 February 2021 using a combination of the groups (1) ‘multiple sclerosis’, ‘MS’ and ‘encephalomyelitis’ and (2) ‘tDCS’ and ‘transcranial direct current stimulation’.
Results
The analysis of the 30 articles included in this review underlined inconsistent effects of tDCS on the motor symptoms of MS based on small sample sizes. However, tDCS showed promising benefits in ameliorating fatigue, pain and cognitive symptoms.
Conclusion
Transcranial direct current stimulation is attractive as a non-drug approach in ameliorating MS symptoms, where other treatment options remain limited. The development of protocols tailored to the individual's own neuroanatomy using high definition tDCS and the introduction of network mapping in the experimental designs might help to overcome the variability between studies.
Objective: Gait adaptation to environmental challenges is fundamental for independent and safe community ambulation. The possibility of precisely studying gait modulation using standardized protocols of gait analysis closely resembling everyday life scenarios is still an unmet need.
Methods: We have developed a fully-immersive virtual reality (VR) environment where subjects have to adjust their walking pattern to avoid collision with a virtual agent (VA) crossing their gait trajectory. We collected kinematic data of 12 healthy young subjects walking in real world (RW) and in the VR environment, both with (VR/A+) and without (VR/A-) the VA perturbation. The VR environment closely resembled the RW scenario of the gait laboratory. To ensure standardization of the obstacle presentation the starting time speed and trajectory of the VA were defined using the kinematics of the participant as detected online during each walking trial.
Results: We did not observe kinematic differences between walking in RW and VR/A-, suggesting that our VR environment per se might not induce significant changes in the locomotor pattern. When facing the VA all subjects consistently reduced stride length and velocity while increasing stride duration. Trunk inclination and mediolateral trajectory deviation also facilitated avoidance of the obstacle.
Conclusions: This proof-of-concept study shows that our VR/A+ paradigm effectively induced a timely gait modulation in a standardized immersive and realistic scenario. This protocol could be a powerful research tool to study gait modulation and its derangements in relation to aging and clinical conditions.
Background
Long-term support of stroke patients living at home is often delivered by family caregivers (FC). We identified characteristics of stroke patients being associated with receiving care by a FC 3-months (3 M) after stroke, assessed positive and negative experiences and individual burden of FC caring for stroke patients and determined factors associated with caregiving experiences and burden of FC 3 M after stroke.
Methods
Data were collected within TRANSIT-Stroke, a regional telemedical stroke-network comprising 12 hospitals in Germany. Patients with stroke/TIA providing informed consent were followed up 3 M after the index event. The postal patient-questionnaire was accompanied by an anonymous questionnaire for FC comprising information on positive and negative experiences of FC as well as on burden of caregiving operationalized by the Caregiver Reaction Assessment and a self-rated burden-scale, respectively. Multivariable logistic and linear regression analyses were performed.
Results
Between 01/2016 and 06/2019, 3532 patients provided baseline and 3 M-follow-up- data and 1044 FC responded to questionnaires regarding positive and negative caregiving experiences and caregiving burden. 74.4% of FC were older than 55 years, 70.1% were women and 67.5% were spouses. Older age, diabetes and lower Barthel-Index in patients were significantly associated with a higher probability of receiving care by a FC at 3 M. Positive experiences of FC comprised the importance (81.5%) and the privilege (70.0%) of caring for their relative; negative experiences of FC included financial difficulties associated with caregiving (20.4%). Median overall self-rated burden was 30 (IQR: 0–50; range 0–100). Older age of stroke patients was associated with a lower caregiver burden, whereas younger age of FC led to higher burden. More than half of the stroke patients in whom a FC questionnaire was completed did self-report that they are not being cared by a FC. This stroke patient group tended to be younger, more often male with less severe stroke and less comorbidities who lived more often with a partner.
Conclusions
The majority of caregivers wanted to care for their relatives but experienced burden at the same time. Elderly patients, patients with a lower Barthel Index at discharge and diabetes are at higher risk of needing care by a family caregiver.
Trial registration
The study was registered at “German Clinical Trial Register”: DRKS00011696. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011696
Background:
Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning.
Methods
Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH.
Results
On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04).
Conclusion
Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has the potential to treat a variety of neurologic and psychiatric disorders. The extent of rTMS-induced neuroplasticity may be dependent on a subject’s brain state at the time of stimulation. Chronic low intensity rTMS (LI-rTMS) has previously been shown to induce beneficial structural and functional reorganisation within the abnormal visual circuits of ephrin-A2A5\(^{-/-}\) mice in ambient lighting. Here, we administered chronic LI-rTMS in adult ephrin-A2A5\(^{-/-}\) mice either in a dark environment or concurrently with voluntary locomotion. One day after the last stimulation session, optokinetic responses were assessed and fluorescent tracers were injected to map corticotectal and geniculocortical projections. We found that LI-rTMS in either treatment condition refined the geniculocortical map. Corticotectal projections were improved in locomotion+LI-rTMS subjects, but not in dark + LI-rTMS and sham groups. Visuomotor behaviour was not improved in any condition. Our results suggest that the beneficial reorganisation of abnormal visual circuits by rTMS can be significantly influenced by simultaneous, ambient visual input and is enhanced by concomitant physical exercise. Furthermore, the observed pathway-specific effects suggest that regional molecular changes and/or the relative proximity of terminals to the induced electric fields influence the outcomes of LI-rTMS on abnormal circuitry.
In large vessel occlusion stroke, recanalization to restore cerebral perfusion is essential but not necessarily sufficient for a favorable outcome. Paradoxically, in some patients, reperfusion carries the risk of increased tissue damage and cerebral hemorrhage. Experimental and clinical data suggest that endothelial cells, representing the interface for detrimental platelet and leukocyte responses, likely play a crucial role in the phenomenon referred to as ischemia/reperfusion (I/R)-injury, but the mechanisms are unknown. We aimed to determine the role of endoglin in cerebral I/R-injury; endoglin is a membrane-bound protein abundantly expressed by endothelial cells that has previously been shown to be involved in the maintenance of vascular homeostasis. We investigated the expression of membranous endoglin (using Western blotting and RT-PCR) and the generation of soluble endoglin (using an enzyme-linked immunosorbent assay of cell culture supernatants) after hypoxia and subsequent reoxygenation in human non-immortalized brain endothelial cells. To validate these in vitro data, we additionally examined endoglin expression in an intraluminal monofilament model of permanent and transient middle cerebral artery occlusion in mice. Subsequently, the effects of recombinant human soluble endoglin were assessed by label-free impedance-based measurement of endothelial monolayer integrity (using the xCELLigence DP system) and immunocytochemistry. Endoglin expression is highly inducible by hypoxia in human brain endothelial monolayers in vitro, and subsequent reoxygenation induced its shedding. These findings were corroborated in mice during MCAO; an upregulation of endoglin was displayed in the infarcted hemispheres under occlusion, whereas endoglin expression was significantly diminished after transient MCAO, which is indicative of shedding. Of note is the finding that soluble endoglin induced an inflammatory phenotype in endothelial monolayers. The treatment of HBMEC with endoglin resulted in a decrease in transendothelial resistance and the downregulation of VE-cadherin. Our data establish a novel mechanism in which hypoxia triggers the initial endothelial upregulation of endoglin and subsequent reoxygenation triggers its release as a vasoactive mediator that, when rinsed into adjacent vascular beds after recanalization, can contribute to cerebral reperfusion injury.
Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is a mainstay of acute ischemic stroke treatment but is associated with bleeding complications, especially after prolonged large vessel occlusion. Recently, inhibition of the NLRP3 inflammasome led to preserved blood–brain barrier (BBB) integrity in experimental stroke in vivo. To further address the potential of NLRP3 inflammasome inhibition as adjunct stroke treatment we used immortalized brain derived endothelial cells (bEnd5) as an in vitro model of the BBB. We treated bEnd5 with rt-PA in combination with the NLRP3 specific inhibitor MCC950 or vehicle under normoxic as well as ischemic (OGD) conditions. We found that rt-PA exerted a cytotoxic effect on bEnd5 cells under OGD confirming that rt-PA is harmful to the BBB. This detrimental effect could be significantly reduced by MCC950 treatment. Moreover, under ischemic conditions, the Cell Index — a sensible indicator for a patent BBB — and the protein expression of Zonula occludens 1 stabilized after MCC950 treatment. At the same time, the extent of endothelial cell death and NLRP3 expression decreased. In conclusion, NLRP3 inhibition can protect the BBB from rt-PA-induced damage and thereby potentially increase the narrow time window for safe thrombolysis in stroke.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.
Rag1\(^{−/−}\) mice, lacking functional B and T cells, have been extensively used as an adoptive transfer model to evaluate neuroinflammation in stroke research. However, it remains unknown whether natural killer (NK) cell development and functions are altered in Rag1\(^{−/−}\) mice as well. This connection has been rarely discussed in previous studies but might have important implications for data interpretation. In contrast, the NOD-Rag1\(^{null}\)IL2rg\(^{null}\) (NRG) mouse model is devoid of NK cells and might therefore eliminate this potential shortcoming. Here, we compare immune-cell frequencies as well as phenotype and effector functions of NK cells in Rag1\(^{−/−}\) and wildtype (WT) mice using flow cytometry and functional in vitro assays. Further, we investigate the effect of Rag1\(^{−/−}\) NK cells in the transient middle cerebral artery occlusion (tMCAO) model using antibody-mediated depletion of NK cells and adoptive transfer to NRG mice in vivo. NK cells in Rag1\(^{−/−}\) were comparable in number and function to those in WT mice. Rag1\(^{−/−}\) mice treated with an anti-NK1.1 antibody developed significantly smaller infarctions and improved behavioral scores. Correspondingly, NRG mice supplemented with NK cells were more susceptible to tMCAO, developing infarctions and neurological deficits similar to Rag1−/− controls. Our results indicate that NK cells from Rag1−/− mice are fully functional and should therefore be considered in the interpretation of immune-cell transfer models in experimental stroke. Fortunately, we identified the NRG mice, as a potentially better-suited transfer model to characterize individual cell subset-mediated neuroinflammation in stroke.
The progressive motor neuropathy (PMN) mouse is a model of an inherited motor neuropathy disease with progressive neurodegeneration. Axon degeneration associates with homozygous mutations of the TBCE gene encoding the tubulin chaperone E protein. TBCE is responsible for the correct dimerization of alpha and beta-tubulin. Strikingly, the PMN mouse also develops a progressive hearing loss after normal hearing onset, characterized by degeneration of the auditory nerve and outer hair cell (OHC) loss. However, the development of this neuronal and cochlear pathology is not fully understood yet. Previous studies with pegylated insulin-like growth factor 1 (peg-IGF-1) treatment in this mouse model have been shown to expand lifespan, weight, muscle strength, and motor coordination. Accordingly, peg-IGF-1 was evaluated for an otoprotective effect. We investigated the effect of peg-IGF-1 on the auditory system by treatment starting at postnatal day 15 (p15). Histological analysis revealed positive effects on OHC synapses of medial olivocochlear (MOC) neuronal fibers and a short-term attenuation of OHC loss. Peg-IGF-1 was able to conditionally restore the disorganization of OHC synapses and maintain the provision of cholinergic acetyltransferase in presynapses. To assess auditory function, frequency-specific auditory brainstem responses and distortion product otoacoustic emissions were recorded in animals on p21 and p28. However, despite the positive effect on MOC fibers and OHC, no restoration of hearing could be achieved. The present work demonstrates that the synaptic pathology of efferent MOC fibers in PMN mice represents a particular form of “efferent auditory neuropathy.” Peg-IGF-1 showed an otoprotective effect by preventing the degeneration of OHCs and efferent synapses. However, enhanced efforts are needed to optimize the treatment to obtain detectable improvements in hearing performances.
In ischemic stroke (IS) impairment of the blood-brain barrier (BBB) has an important role in the secondary deterioration of neurological function. BBB disruption is associated with ischemia-induced inflammation, brain edema formation, and hemorrhagic infarct transformation, but the underlying mechanisms are incompletely understood. Dysfunction of endothelial cells (EC) may play a central role in this process. Although neuronal NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome upregulation is an established trigger of inflammation in IS, the contribution of its expression in EC is unclear. We here used brain EC, exposed them to oxygen and glucose deprivation (OGD) in vitro, and analyzed their survival depending on inflammasome inhibition with the NLRP3-specific drug MCC950. During OGD, EC death could significantly be reduced when targeting NLRP3, concomitant with diminished endothelial NLRP3 expression. Furthermore, MCC950 led to reduced levels of Caspase 1 (p20) and activated Gasdermin D as markers for pyroptosis. Moreover, inflammasome inhibition reduced the secretion of pro-inflammatory chemokines, cytokines, and matrix metalloproteinase-9 (MMP9) in EC. In a translational approach, IS was induced in C57Bl/6 mice by 60 mins transient middle cerebral artery occlusion and 23 hours of reperfusion. Stroke volume, functional outcome, the BBB integrity, and-in good agreement with the in vitro results-MMP9 secretion as well as EC survival improved significantly in MCC950-treated mice. In conclusion, our results establish the NLRP3 inflammasome as a critical pathogenic effector of stroke-induced BBB disruption by activating inflammatory signaling cascades and pyroptosis in brain EC.
Both nerve injury and complex regional pain syndrome (CRPS) can result in chronic pain. In traumatic neuropathy, the blood nerve barrier (BNB) shielding the nerve is impaired—partly due to dysregulated microRNAs (miRNAs). Upregulation of microRNA-21-5p (miR-21) has previously been documented in neuropathic pain, predominantly due to its proinflammatory features. However, little is known about other functions. Here, we characterized miR-21 in neuropathic pain and its impact on the BNB in a human-murine back translational approach. MiR-21 expression was elevated in plasma of patients with CRPS as well as in nerves of mice after transient and persistent nerve injury. Mice presented with BNB leakage, as well as loss of claudin-1 in both injured and spared nerves. Moreover, the putative miR-21 target RECK was decreased and downstream Mmp9 upregulated, as was Tgfb. In vitro experiments in human epithelial cells confirmed a downregulation of CLDN1 by miR-21 mimics via inhibition of the RECK/MMP9 pathway but not TGFB. Perineurial miR-21 mimic application in mice elicited mechanical hypersensitivity, while local inhibition of miR-21 after nerve injury reversed it. In summary, the data support a novel role for miR-21, independent of prior inflammation, in elicitation of pain and impairment of the BNB via RECK/MMP9.
Experimental evidence has emerged that local platelet activation contributes to inflammation and infarct formation in acute ischemic stroke (AIS) which awaits confirmation in human studies. We conducted a prospective observational study on 258 consecutive patients undergoing mechanical thrombectomy (MT) due to large-vessel-occlusion stroke of the anterior circulation (08/2018-05/2020). Intraprocedural microcatheter aspiration of 1 ml of local (occlusion condition) and systemic arterial blood samples (self-control) was performed according to a prespecified protocol. The samples were analyzed for differential leukocyte counts, platelet counts, and plasma levels of the platelet-derived neutrophil-activating chemokine C-X-C-motif ligand (CXCL) 4 (PF-4), the neutrophil attractant CXCL7 (NAP-2), and myeloperoxidase (MPO). The clinical-biological relevance of these variables was corroborated by specific associations with molecular-cellular, structural-radiological, hemodynamic, and clinical-functional parameters. Seventy consecutive patients fulfilling all predefined criteria entered analysis. Mean local CXCL4 (+ 39%: 571 vs 410 ng/ml, P = .0095) and CXCL7 (+ 9%: 693 vs 636 ng/ml, P = .013) concentrations were higher compared with self-controls. Local platelet counts were lower (- 10%: 347,582 vs 383,284/µl, P = .0052), whereas neutrophil counts were elevated (+ 10%: 6022 vs 5485/µl, P = 0.0027). Correlation analyses revealed associations between local platelet and neutrophil counts (r = 0.27, P = .034), and between CXCL7 and MPO (r = 0.24, P = .048). Local CXCL4 was associated with the angiographic degree of reperfusion following recanalization (r = - 0.2523, P = .0479). Functional outcome at discharge correlated with local MPO concentrations (r = 0.3832, P = .0014) and platelet counts (r = 0.288, P = .0181). This study provides human evidence of cerebral platelet activation and platelet-neutrophil interactions during AIS and points to the relevance of per-ischemic thrombo-inflammatory mechanisms to impaired reperfusion and worse functional outcome following recanalization.
Ischemic disorders are the leading cause of death worldwide. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) are thought to affect the outcome of ischemic stroke. However, it is under debate whether activation or inhibition of ERK1/2 is beneficial. In this study, we report that the ubiquitous overexpression of wild-type ERK2 in mice (ERK2\(^{wt}\)) is detrimental after transient occlusion of the middle cerebral artery (tMCAO), as it led to a massive increase in infarct volume and neurological deficits by increasing blood–brain barrier (BBB) leakiness, inflammation, and the number of apoptotic neurons. To compare ERK1/2 activation and inhibition side-by-side, we also used mice with ubiquitous overexpression of the Raf-kinase inhibitor protein (RKIP\(^{wt}\)) and its phosphorylation-deficient mutant RKIP\(^{S153A}\), known inhibitors of the ERK1/2 signaling cascade. RKIP\(^{wt}\) and RKIP\(^{S153A}\) attenuated ischemia-induced damages, in particular via anti-inflammatory signaling. Taken together, our data suggest that stimulation of the Raf/MEK/ERK1/2-cascade is severely detrimental and its inhibition is rather protective. Thus, a tight control of the ERK1/2 signaling is essential for the outcome in response to ischemic stroke.
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
Parkinson’s Disease (PD) constitutes a major healthcare burden in Europe. Accounting for aging alone, ~700,000 PD cases are predicted by 2040. This represents an approximately 56% increase in the PD population between 2005 and 2040, with a consequent rise in annual disease‐related medical costs. Gait and balance disorders are a major problem for patients with PD and their caregivers, mainly because to their correlation with falls. Falls occur as a result of a complex interaction of risk factors. Among them, Freezing of Gait (FoG) is a peculiar gait derangement characterized by a sudden and episodic inability to produce effective stepping, causing falls, mobility restrictions, poor quality of life, and increased morbidity and mortality. Between 50–70% of PD patients have FoG and/or falls after a disease duration of 10 years, only partially and inconsistently improved by dopaminergic treatment and Deep Brain Stimulation (DBS). Treatment-induced worsening has been also observed under certain conditions. Effective treatments for gait disturbances in PD are lacking, probably because of the still poor understanding of the supraspinal locomotor network.
In my thesis, I wanted to expand our knowledge of the supraspinal locomotor network and in particular the contribution of the basal ganglia to the control of locomotion. I believe this is a key step towards new preventive and personalized therapies for postural and gait problems in patients with PD and related disorders. In addition to patients with PD, my studies also included people affected by Progressive Supranuclear Palsy (PSP). PSP is a rare primary progressive parkinsonism characterized at a very early disease stage by poor balance control and frequent backwards falls, thus providing an in vivo model of dysfunctional locomotor control.
I focused my attention on one of the most common motor transitions in daily living, the initiation of gait (GI). GI is an interesting motor task and a relevant paradigm to address balance and gait impairments in patients with movement disorders, as it is associated with FoG and high risk of falls. It combines a preparatory (i.e., the Anticipatory Postural Adjustments [APA]) and execution phase (the stepping) and allows the study of movement scaling and timing as an expression of muscular synergies, which follow precise and online feedback information processing and integration into established feedforward patterns of motor control.
By applying a multimodal approach that combines biomechanical assessments and neuroimaging investigations, my work unveiled the fundamental contribution of striatal dopamine to GI in patients with PD. Results in patients with PSP further supported the fundamental role of the striatum in GI execution, revealing correlations between the metabolic intake of the left caudate nucleus with diverse GI measurements. This study also unveiled the interplay of additional brain areas in the motor control of GI, namely the Thalamus, the Supplementary Motor Area (SMA), and the Cingulate cortex. Involvement of cortical areas was also suggested by the analysis of GI in patients with PD and FoG. Indeed, I found major alterations in the preparatory phase of GI in these patients, possibly resulting from FoG-related deficits of the SMA. Alterations of the weight shifting preceding the stepping phase were also particularly important in PD patients with FoG, thus suggesting specific difficulties in the integration of somatosensory information at a cortical level. Of note, all patients with PD showed preserved movement timing of GI, possibly suggesting preserved and compensatory activity of the cerebellum. Postural abnormalities (i.e., increased trunk and thigh flexion) showed no relationship with GI, ruling out an adaptation of the motor pattern to the altered postural condition. In a group of PD patients implanted with DBS, I further explored the pathophysiological functioning of the locomotor network by analysing the timely activity of the Subthalamic Nucleus (STN) during static and dynamic balance control (i.e., standing and walking). For this study, I used novel DBS devices capable of delivering stimulation and simultaneously recording Local Field Potentials (LFP) of the implanted nucleus months and years after surgery. I showed a gait-related frequency shift in the STN activity of PD patients, possibly conveying cortical (feedforward) and cerebellar (feedback) information to mesencephalic locomotor areas. Based on this result, I identified for each patient a Maximally Informative Frequency (MIF) whose power changes can reliably classify standing and walking conditions. The MIF is a promising input signal for new DBS devices that can monitor LFP power modulations to timely adjust the stimulation delivery based on the ongoing motor task (e.g., gait) performed by the patient (adaptive DBS).
Altogether my achievements allowed to define the role of different cortical and subcortical brain areas in locomotor control, paving the way for a better understanding of the pathophysiological dynamics of the supraspinal locomotor network and the development of tailored therapies for gait disturbances and falls prevention in PD and related disorders.
Deep brain stimulation (DBS) of the subthalamic nucleus or the globus pallidus is an established treatment for Parkinson’s disease (PD) that yields a marked and lasting improvement of motor symptoms. Yet, DBS benefit on gait disturbances in PD is still debated and can be a source of dissatisfaction and poor quality of life. Gait disturbances in PD encompass a variety of clinical manifestations and rely on different pathophysiological bases. While gait disturbances arising years after DBS surgery can be related to disease progression, early impairment of gait may be secondary to treatable causes and benefits from DBS reprogramming. In this review, we tackle the issue of gait disturbances in PD patients with DBS by discussing their neurophysiological basis, providing a detailed clinical characterization, and proposing a pragmatic programming approach to support their management.
Background
Although Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene (GLA), women may develop severe symptoms. We investigated X-chromosomal inactivation patterns (XCI) as a potential determinant of symptom severity in FD women.
Patients and Methods
We included 95 women with mutations in GLA (n = 18 with variants of unknown pathogenicity) and 50 related men, and collected mouth epithelial cells, venous blood, and skin fibroblasts for XCI analysis using the methylation status of the androgen receptor gene. The mutated X-chromosome was identified by comparison of samples from relatives. Patients underwent genotype categorization and deep clinical phenotyping of symptom severity.
Results
43/95 (45%) women carried mutations categorized as classic. The XCI pattern was skewed (i.e., ≥75:25% distribution) in 6/87 (7%) mouth epithelial cell samples, 31/88 (35%) blood samples, and 9/27 (33%) skin fibroblast samples. Clinical phenotype, α-galactosidase A (GAL) activity, and lyso-Gb3 levels did not show intergroup differences when stratified for X-chromosomal skewing and activity status of the mutated X-chromosome.
Conclusions
X-inactivation patterns alone do not reliably reflect the clinical phenotype of women with FD when investigated in biomaterial not directly affected by FD. However, while XCI patterns may vary between tissues, blood frequently shows skewing of XCI patterns.
Fabry disease (FD) is a rare life-threatening disorder caused by deficiency of the alpha-galactosidase A (GLA) enzyme with a characteristic pain phenotype. Impaired GLA production or function leads to the accumulation of the cell membrane compound globotriaosylceramide (Gb3) in the neurons of the dorsal root ganglia (DRG) of FD patients. Applying immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT PCR) analysis on DRG tissue of the GLA knockout (KO) mouse model of FD, we address the question of how Gb3 accumulation may contribute to FD pain and focus on the immune system and pain-associated ion channel gene expression. We show a higher Gb3 load in the DRG of young (<6 months) (p < 0.01) and old (≥12 months) (p < 0.001) GLA KO mice compared to old wildtype (WT) littermates, and an overall suppressed immune response in the DRG of old GLA KO mice, represented by a reduced number of CD206\(^+\) macrophages (p < 0.01) and lower gene expression levels of the inflammation-associated targets interleukin(IL)1b (p < 0.05), IL10 (p < 0.001), glial fibrillary acidic protein (GFAP) (p < 0.05), and leucine rich alpha-2-glycoprotein 1 (LRG1) (p < 0.01) in the DRG of old GLA KO mice compared to old WT. Dysregulation of immune-related genes may be linked to lower gene expression levels of the pain-associated ion channels calcium-activated potassium channel 3.1 (KCa3.1) and transient receptor potential ankyrin 1 channel (TRPA1). Ion channel expression might further be disturbed by impaired sphingolipid recruitment mediated via the lipid raft marker flotillin-1 (FLOT1). This impairment is represented by an increased number of FLOT1\(^+\) DRG neurons with a membranous expression pattern in old GLA KO mice compared to young GLA KO, young WT, and old WT mice (p < 0.001 each). Further, we provide evidence for aberrant behavior of GLA KO mice, which might be linked to dysregulated ion channel gene expression levels and disturbed FLOT1 distribution patterns. Behavioral testing revealed mechanical hypersensitivity in young (p < 0.01) and old (p < 0.001) GLA KO mice compared to WT, heat hypersensitivity in young GLA KO mice (p < 0.001) compared to WT, age-dependent heat hyposensitivity in old GLA KO mice (p < 0.001) compared to young GLA KO mice, and cold hyposensitivity in young (p < 0.001) and old (p < 0.001) GLA KO mice compared to WT, which well reflects the clinical phenotype observed in FD patients.
Recovery of upper limb (UL) impairment after stroke is limited in stroke survivors. Since stroke can be considered as a network disorder, neuromodulation may be an approach to improve UL motor dysfunction. Here, we evaluated the effect of high-frequency stimulation (HFS) of the subthalamic nucleus (STN) in rats on forelimb grasping using the single-pellet reaching (SPR) test after stroke and determined costimulated brain regions during STN-HFS using 2-[\(^{18}\)F]Fluoro-2-deoxyglucose-([\(^{18}\)F]FDG)-positron emission tomography (PET). After a 4-week training of SPR, photothrombotic stroke was induced in the sensorimotor cortex of the dominant hemisphere. Thereafter, an electrode was implanted in the STN ipsilateral to the infarction, followed by a continuous STN-HFS or sham stimulation for 7 days. On postinterventional day 2 and 7, an SPR test was performed during STN-HFS. Success rate of grasping was compared between these two time points. [\(^{18}\)F]FDG-PET was conducted on day 2 and 3 after stroke, without and with STN-HFS, respectively. STN-HFS resulted in a significant improvement of SPR compared to sham stimulation. During STN-HFS, a significantly higher [\(^{18}\)F]FDG-uptake was observed in the corticosubthalamic/pallidosubthalamic circuit, particularly ipsilateral to the stimulated side. Additionally, STN-HFS led to an increased glucose metabolism within the brainstem. These data demonstrate that STN-HFS supports rehabilitation of skilled forelimb movements, probably by retuning dysfunctional motor centers within the cerebral network.
In der vorliegenden Arbeit wurde die Eignung der im Rahmen der Routinediagnostik verfügbaren, aber unzu¬reichend charakterisierten Analyten Beta-2-Mikroglobulin (β2-Mikroglobulin), Laktat und Angiotensin-Converting Enzyme (ACE) als Biomarker untersucht. Dazu wurden 6.310 an der Neurologischen Klinik des Universitätsklinikums Würzburg gewonnene Liquorproben analysiert. Näher analysiert wurden 276 Fälle mit nicht entzünd¬lichen neurologischen Erkrankungen (NIND; Kontrollgruppe) und 438 nicht immuntherapeutisch behandelte MS-Fälle (Untersuchugsgruppe). Bei den MS-Fällen wurde die Verlaufs¬form und Krankheitsaktivität (klinische Schübe, Progressionsindex) dokumentiert. Es zeigte sich eine deutliche Altersabhängigkeit der Liquorspiegel von β2-Mikroglobulin, Laktat und ACE in der MS- und Kontrollgruppe, was für die sich anschließenden weiteren Vergleichsuntersuchungen eine Korrektur erforderte und zumindest teilweise die wider¬sprüchliche Datenlage bisheriger Studien erklären könnte. MS-Fälle zeigten im Liquor im Vergleich zu Kontrollen erhöhte β2-Mikroglobulin- und Laktat- sowie er¬niedrigte ACE-Spiegel. In beiden Gruppen korrelierten die β2-Mikroglobulin- und ACE-Spiegel positiv miteinander. Bei der getrennten Analyse der MS-Verlaufsformen zeigten Fälle mit klinisch isoliertem Syndrom (CIS) und schubförmig remittierender MS (RRMS) erhöhte β2-Mikroglobulin-Spiegel, Fälle mit sekundär bzw. primär pro¬gredienter MS (SPMS bzw. PPMS) dagegen nicht. Die Laktat-Spiegel waren lediglich bei CIS-Fällen erhöht. Fälle mit schubförmigen Verläufen zeigten reduzierte ACE-Spiegel. Die Krankheitsaktivität wurde durch die Parameter nicht zuverlässig abgebildet. Die Laktat-Spiegel waren tendenziell bei einem Schub erhöht, das Ergebnis war nach Korrektur aber nicht mehr signifikant. Die Laktat-Spiegel korrelierten zudem positiv mit dem Progressionsindex. Die vorliegenden Befunde belegen, dass die untersuchten Analyten alleine nicht in der Lage sind, die Verlaufsform, Krankheitsaktivität und -dauer zu beurteilen. Die deutlichen Unterschiede zwischen schubförmigen und chronisch progredienten Verläufen unterstützen jedoch die Hypothese unterschiedlicher zugrundeliegender Pathomechanismen und könnten als Ausgangspunkt für weitere Untersuchungen dienen.
Eine Vielzahl von Patienten mit fortgeschrittener, beziehungsweise dialysepflichtiger Niereninsuffizienz entwickeln eine Polyneuropathie. Die Pathogenese der urämischen Neuropathie (UN) ist nicht geklärt, sodass auf der Suche nach dem Pathomechanismus auch ein Vitamin-B12-Mangel diskutiert werden muss, da dieser ähnliche Symptome wie die UN hervorrufen kann. Ziel dieser Studie war es, den Zusammenhang zwischen den Parametern des Vitamin-B12-Stoffwechsels und der UN darzustellen. In einer prospektiven Studie mit insgesamt 54 teilnehmenden Patienten wurden diese vor und nach einer Vitamin-B12-Substitution laborchemisch untersucht. Zudem erhielten die Patienten neben einer klinischen Untersuchung eine elektroneurographische Diagnostik des N. suralis und des N. tibialis, sowie eine QST-Untersuchung.
In den letzten Jahren gewann das Konzept der Paranodopathien als eigene Krankheitsentität der inflammatorischen Polyneuropathien zunehmend an Bedeutung. Die Forschung konzentrierte sich dabei überwiegend auf die chronisch inflammatorische Polyradikuloneuropathie (CIDP). In dieser Arbeit werden (para-)nodale Antikörper gegen Neurofascin-155, panNeurofascin, Contactin-1 und Caspr-1 in einer großen Kohorte von Patienten mit Guillain-Barré-Syndrom (GBS) und CIDP nachgewiesen. Patienten mit Anti-panNeurofascin-Antikörpern zeigten besonders schwere Verlaufsformen. Patienten mit anderen (para-)nodalen Antikörpern zeigten je nach IgG-Subklasse der Antikörper spezifische klinische Merkmale und ein unterschiedliches Ansprechen auf die Therapie. Die Arbeit zeigt, dass die Bestimmung (para-)nodaler Antikörper bei Patienten mit GBS und CIDP im klinischen Alltag zur Einordung der Prognose und Therapieplanung sinnvoll sein kann.
In dieser Dissertation untersuchten wir die neuronalen Korrelate des Training-Effektes einer auditorischen P300 Gehirn-Computer Schnittstelle mittels fMRI Analyse in einem prä-post Design mit zehn gesunden Testpersonen. Wir wiesen in drei Trainings-sitzungen einen Trainingseffekt in der EEG-Analyse der P300 Welle nach und fanden entsprechende Kontraste in einer prä-post Analyse von fMRI Daten, wobei in allen fünf Sitzungen das gleiche Paradigma verwendet wurde. In der fMRI Analyse fanden wir fol-gende Ergebnisse: in einem Target-/ Nichttarget Kontrast zeigte sich verstärkte Aktivie-rung in Generatorregionen der P300 Welle (temporale und inferiore frontale Regionen) und interessanterweise auch in motorassoziierten Arealen, was höhere kognitiver Pro-zesse wie Aufmerksamkeitslenkung und Arbeitsspeicher widerspiegeln könnte. Der Kon-trast des Trainingseffektes zeigte nach dem Training einen stärkeren Rebound Effekt im Sinne einer verstärkten Aktivierung in Generatorregionen der P300 Welle, was eine ver-besserte Erkennung und Prozessierung von Target-Stimuli reflektieren könnte. Eine Ab-nahme von Aktivierung in frontalen Arealen in diesem Kontrast könnte durch effizientere Abläufe kognitiver Prozesse und des Arbeitsgedächtnis erklärt werden.
Die (Para-)nodopathie ist neben der primär axonalen und der primär demyelinisierenden Polyneuropathie eine neue Krankheitsentität, die sich durch eine Schädigung der Funktion des Ranvierschen Schnürringes auszeichnet. Die Forschung zu (para-)nodalen Autoantikörpern fokussierte sich bislang hauptsächlich auf Neurofascin-155- und Contactin-1-Autoantikörper der Subklasse IgG4.
In dieser Studie wurden die Seren von insgesamt 264 PatientInnen mit CIDP, GBS oder anderen Formen von Polyneuropathien mittels Bindungsassays an murinen Ischiadicuszupfnerven und gegebenenfalls ELISA auf (para-)nodale Autoantikörper gescrennt. Positive Autoantikörperbefunde wurden bei IgG-Autoantikörpern mittels Bindungsassays an transfizierten HEK-293-Zellen und bei IgM-Autoantikörpern mittels Western Blot bestätigt. ELISA Untersuchungen dienten zur näheren Spezifizierung. Weiterhin wurde die zeitabhängige Wirkung von Contactin-1-Autoantikörpern im Zellkulturmodell untersucht.
Die im folgenden dargestellten Ergebnisse zeigen, dass die (Para-)nodopathie nicht auf die bisher am häufigsten beschriebene Erkrankung mit IgG4-Autoantikörpern beschränkt werden sollte.
Bei dem extrem schwer betroffenen IgG-Patient 1 konnte ein Pan-Neurofascin-IgG3-Autoantikörper nachgewiesen werden. Als charakteristische Symptome für diese Autoantikörper konnten in Übereinstimmung mit weiteren Fallberichten Tetraplegie, Beatmungspflichtigkeit sowie eine schwere Hirnnervenbeteiligung bis zur Locked-In-Symptomatik identifiziert werden. Diese Patienten heben sich deutlich von den PatientInnen mit den bisher hauptsächlich beschriebenen Neurofascin-155-IgG4-Autoantikörpern ab, die wie IgG-Patient 2 charakteristischerweise in jungem Alter an einer CIDP mit Tremor ohne Besserung unter IVIG-Therapie leiden.
Es wurden fünf PatientInnen mit Neurofascin-155-IgM-Autoantikörpern identifiziert, die eine akut beginnende Erkrankung mit Tetraparese, Tremor und neuropathischen Schmerzen zeigten. Ob sich dieser Phänotyp als charakteristisch für eine Neurofascin-155-IgM-(Para-)nodopathie bestätigt, sollte in weiteren Studien untersucht werden.
Im murinen Zellkulturmodell an cerebellären Neuronen und Spinalganglienneuronen zeigte sich nach Inkubation mit Contactin-1-IgG-Patientenantikörpern eine zeitabhängige, rasch reversible Verminderung der Contactin-1-Protein-Expression in immunhistochemischen Färbungen sowie Western Blots, die durch eine Internalisierung des Contactin-1-Proteins erklärbar wäre. Der Angriff von Autoantikörpern an Spinalganglienneuronen und cerebellären Neurone sollte in weitere pathophysiologische Überlegungen miteinbezogen werden, da hierdurch typische Symptome der (Para-)nodopathie wie eine sensible Ataxie oder ein cerebellärer Tremor erklärt werden könnten.
Objectives
The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.
Methods
Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.
Results
Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms.
Conclusion
We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.
Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice
(2022)
Background
Antigen-specific neuroinflammation and neurodegeneration are characteristic for neuroimmunological diseases. In Parkinson’s disease (PD) pathogenesis, α-synuclein is a known culprit. Evidence for α-synuclein-specific T cell responses was recently obtained in PD. Still, a causative link between these α-synuclein responses and dopaminergic neurodegeneration had been lacking. We thus addressed the functional relevance of α-synuclein-specific immune responses in PD in a mouse model.
Methods
We utilized a mouse model of PD in which an Adeno-associated Vector 1/2 serotype (AAV1/2) expressing human mutated A53T-α-Synuclein was stereotactically injected into the substantia nigra (SN) of either wildtype C57BL/6 or Recombination-activating gene 1 (RAG1)\(^{-/-}\) mice. Brain, spleen, and lymph node tissues from different time points following injection were then analyzed via FACS, cytokine bead assay, immunohistochemistry and RNA-sequencing to determine the role of T cells and inflammation in this model. Bone marrow transfer from either CD4\(^{+}\)/CD8\(^{-}\), CD4\(^{-}\)/CD8\(^{+}\), or CD4\(^{+}\)/CD8\(^{+}\) (JHD\(^{-/-}\)) mice into the RAG-1\(^{-/-}\) mice was also employed. In addition to the in vivo studies, a newly developed A53T-α-synuclein-expressing neuronal cell culture/immune cell assay was utilized.
Results
AAV-based overexpression of pathogenic human A53T-α-synuclein in dopaminergic neurons of the SN stimulated T cell infiltration. RNA-sequencing of immune cells from PD mouse brains confirmed a pro-inflammatory gene profile. T cell responses were directed against A53T-α-synuclein-peptides in the vicinity of position 53 (68–78) and surrounding the pathogenically relevant S129 (120–134). T cells were required for α-synuclein-induced neurodegeneration in vivo and in vitro, while B cell deficiency did not protect from dopaminergic neurodegeneration.
Conclusions
Using T cell and/or B cell deficient mice and a newly developed A53T-α-synuclein-expressing neuronal cell culture/immune cell assay, we confirmed in vivo and in vitro that pathogenic α-synuclein peptide-specific T cell responses can cause dopaminergic neurodegeneration and thereby contribute to PD-like pathology.
At any moment in time, cells coordinate and balance their calcium ion (Ca\(^{2+}\)) fluxes. The term ‘Ca\(^{2+}\) homeostasis’ suggests that balancing resting Ca2+ levels is a rather static process. However, direct ER Ca\(^{2+}\) imaging shows that resting Ca\(^{2+}\) levels are maintained by surprisingly dynamic Ca\(^{2+}\) fluxes between the ER Ca\(^{2+}\) store, the cytosol, and the extracellular space. The data show that the ER Ca\(^{2+}\) leak, continuously fed by the high-energy consuming SERCA, is a fundamental driver of resting Ca\(^{2+}\) dynamics. Based on simplistic Ca\(^{2+}\) toolkit models, we discuss how the ER Ca\(^{2+}\) leak could contribute to evolutionarily conserved Ca\(^{2+}\) phenomena such as Ca\(^{2+}\) entry, ER Ca\(^{2+}\) release, and Ca\(^{2+}\) oscillations.
Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a steroid-responsive meningoencephalomyelitis, sometimes presenting with atypical clinical signs such as movement disorders or psychiatric and autonomic features. Beyond clinical presentation and imaging, diagnosis relies on detection of GFAP-antibodies (AB) in CSF. Using quantitative behavioral, serologic, and immunohistochemical analyses, we characterize two patients longitudinally over 18–24 months who presented with rapidly progressive neurocognitive deterioration in the context of GFAP-AB in CSF and unremarkable cranial MRI studies. Intensified immunotherapy was associated with clinical stabilization. The value of GFAP-AB screening in selected cases of rapidly progressive dementias is discussed.
Relevance of Religiosity for Coping Strategies and Disability in Patients with Fibromyalgia Syndrome
(2022)
Coping strategies are essential for the outcome of chronic pain. This study evaluated religiosity in a cohort of patients with fibromyalgia syndrome (FMS), its effect on pain and other symptoms, on coping and FMS-related disability. A total of 102 FMS patients were recruited who filled in questionnaires, a subgroup of 42 patients participated in a face-to-face interview, and data were evaluated by correlation and regression analyses. Few patients were traditionally religious, but the majority believed in a higher existence and described their spirituality as "transcendence conviction". The coping strategy "praying-hoping" and the ASP dimension "religious orientation" (r = 0.5, P < 0.05) showed a significant relationship independent of the grade of religiosity (P < 0.05). A high grade of belief in a higher existence was negatively associated with the choice of ignoring as coping strategy (r = - 0.4, P < 0.05). Mood and affect-related variables had the highest impact on disability (b = 0.5, P < 0.05). In this cohort, the grade of religiosity played a role in the choice of coping strategies, but had no effects on health and mood outcome.
Aging is known to be a risk factor for structural abnormalities and functional decline in the nervous system. Characterizing age-related changes is important to identify putative pathways to overcome deleterious effects and improve life quality for the elderly. In this study, the peripheral nervous system of 24-month-old aged C57BL/6 mice has been investigated and compared to 12-month-old adult mice. Aged mice showed pathological alterations in their peripheral nerves similar to nerve biopsies from elderly human individuals, with nerve fibers showing demyelination and axonal damage. Such changes were lacking in nerves of adult 12-month-old mice and adult, non-aged humans. Moreover, neuromuscular junctions of 24-month-old mice showed increased denervation compared to adult mice. These alterations were accompanied by elevated numbers of macrophages in the peripheral nerves of aged mice. The neuroinflammatory conditions were associated with impaired myelin integrity and with a decline of nerve conduction properties and muscle strength in aged mice.
To determine the pathological impact of macrophages in the aging mice, macrophage depletion was performed in mice by oral administration of CSF-1R specific kinase (c-FMS) inhibitor PLX5622 (300 mg/kg body weight), which reduced the number of macrophages in the peripheral nerves by 70%. The treated mice showed attenuated demyelination, less muscle denervation and preserved muscle strength. This indicates that macrophage-driven inflammation in the peripheral nerves is partially responsible for the age-related neuropathy in mice.
Based on previous observations that systemic inflammation can accelerate disease progression in mouse models of neurodegenerative diseases, it was hypothesized that systemic inflammation can exacerbate the peripheral neuropathy found in aged mice. To investigate this hypothesis, aged C57BL/6 mice were intraperitoneally injected with a single dose of lipopolysaccharide (LPS; 500 μg/kg body weight) to induce systemic inflammation by mimicking bacterial infection, mostly via activation of Toll-like receptors (TLRs). Altered endoneurial macrophage activation, highlighted by Trem2 downregulation, was found in LPS injected aged mice one month after injection. This was accompanied by a so far rarely observed form of axonal perturbation, i.e., the occurrence of “dark axons” characterized by a damaged cytoskeleton and an increased overall electron density of the axoplasm. At the same time, however, LPS injection reduced demyelination and muscle denervation in aged mice. Interestingly, TREM2 deficiency in aged mice led to similar changes to LPS injection. This suggests that LPS injection likely mitigates aging-related demyelination and muscle denervation via Trem2 downregulation.
Taken together, this study reveals the role of macrophage-driven inflammation as a pathogenic mediator in age-related peripheral neuropathy, and that targeting macrophages might be an option to mitigate peripheral neuropathies in aging individuals. Furthermore, this study shows that systemic inflammation may be an ambivalent modifier of age-related nerve damage, leading to a distinct type of axonal perturbation, but in addition to functionally counteracting, dampened demyelination and muscle denervation. Translationally, it is plausible to assume that tipping the balance of macrophage polarization to one direction or the other may determine the functional outcome in the aging peripheral nervous system of the elderly.
Neurodegeneration plays an essential role in Parkinson’s disease (PD). Several crucial neuronal pro-and antidegeneration markers were described to be altered in disease models accompanied by neurodegeneration. In the AAV1/2-A53T-aSyn PD rat model progressive time-dependent motor impairment and neurodegeneration in the nigrostriatal tract starting from 2 weeks after PD model induction could be found. Downregulation of Nrf2 in SN and nigrostriatal axon localization, a trend of Tau downregulation in SN and upregulation in axon localization in the AAV1/2-A53T-aSyn PD rat model were observed, indicating potential therapeutic value of these two molecular targets in PD. No alterations of SARM1 and NMNAT2 could be detected, indicating little relevance of these two molecules with our AAV1/2-A53T-aSyn rat model.
Die WHO definiert Gesundheit als völliges körperliches, geistiges und soziales Wohlbefinden. Während diese ganzheitliche Betrachtungsweise seit Menschengedenken nahezu weltweit das Gesundheitswesen prägt, hat die Medizin in Europa mit der naturwissenschaftlichen Erkenntnisrevolution einen Sonderweg eingeschlagen. Hier wird der kranke Organismus in erster Linie als defekter Apparat gesehen, der mit ausgeklügelter Technik zu reparieren ist. Aber auch präziseste Qualitätsarbeit stößt dabei oft an Leistungsgrenzen, weil sie als seelenlos erlebt wird. Daher sehen heute viele Fachgebiete die Notwendigkeit, ihre Behandlungskonzepte zu beseelen und ihre Behandlungserfolge auch anhand der subjektiv von Patienten empfundenen Lebensqualität zu beurteilen. Für die Ermittlung dieses PRO kommen etablierte psychometrische Testverfahren in Frage, die sich auch für routinemäßige Verlaufskontrollen eignen.
In der vorliegenden Arbeit wurde am Beispiel der mHE geprüft, welchen Nutzen eine PRO-Bestimmung bei der Verlaufskontrolle haben kann. Dazu wurde eine prospektive Studie mit anfänglich 75 Patienten durchgeführt. Alle hatten eine mHE und waren entweder alkoholbedingt oder aus anderen Gründen schwer leberkrank. An vier Terminen im Abstand von sechs Monaten wurden die kognitive Leistungsfähigkeit und der emotionale Status überprüft. Die Patienten zeigten anfänglich kognitive Einschränkungen, die sich im Verlauf der individuell abgestimmten Behandlung deutlich verbesserten oder ganz verschwanden. Die globale Testung mit dem MoCA ergab eine hochsignifikante Normalisierung im ersten Behandlungsjahr. Die MoCA-Werte am Studienanfang und -ende waren von der Erkrankungsursache unabhängig. Dieser Befund differenzierte sich in den Spezialtests TMT, PHES und NHPT. Hier zeigten die alkoholbedingt Erkrankten durchweg schlechtere Leistungen als die nicht-alkoholbedingt Erkrankten, erholten sich aber in der Regel auch deutlicher.
Die seelische Gestimmtheit gemäß BDI-II und die mit dem SF-36 MCS ermittelte psychosoziale Befindlichkeit waren in beiden Patientengruppen von Anfang an vergleichsweise günstig. Dabei hatten die alkoholbedingt Erkrankten die besseren Werte, speziell der BDI-II zeigte bei ihnen nach einem halben Jahr eine zusätzliche und bleibende Stimmungsaufhellung an. Der SF-36 PCS zum Körpererleben zeigte hingegen, dass sich die alkoholbedingt Erkrankten zu Studienbeginn in einer deutlich schlechteren Verfassung befanden. Diese verbesserte sich aber kontinuierlich, sodass nach 1,5 Jahren kein Unterschied mehr zu den nicht-alkoholbedingt Erkrankten bestand. Aus diesen Befunden und dem reichhaltigen Erfahrungsgut zur Alkoholkrankheit wird geschlossen, dass der Genesungsprozess bei alkoholbedingtem Leberversagen viel komplexer ist als bei nicht-alkoholbedingtem Leberversagen. Er könnte wesentlich mehr Zeit erfordern und wird offensichtlich anders erlebt. Dieser Patientengruppe könnten besondere physio- und gesprächstherapeutische Angebote eine große Hilfe sein.
Die Arbeit zeigt, dass es möglich ist, mit wenig Aufwand komplementär zu den klinischen Verlaufsbefunden einen informativen PRO-Bericht zu erhalten. Er hilft Angehörigen und medizinischem Personal, die persönlichen Nöte und Hoffnungen der Patienten besser zu verstehen und gegebenenfalls einen Korrekturbedarf im Umgang zu erkennen. Hinzu kam im vorliegenden Fall die Erkenntnis, dass die alkoholbedingt Erkrankten in ihrem Kranksein anders betroffen waren. Die Gründe dafür sind im Nachhinein plausibel, der Sachverhalt als solcher wäre aber ohne diese Spezialuntersuchung wohl nicht erkannt worden. Das Beispiel der PRO-Ermittlung bei der mHE macht den praktischen Wert einer Berücksichtigung des gesamtheitlichen Gesundheitskonzepts der WHO auch in der technikzentrierten „westlichen Medizin“ deutlich.
Ziel dieser Studie war es, zu untersuchen, ob dendritische Zellen eine Rolle beim ischämischen Schlaganfall spielen. Zur Beantwortung dieser Fragestellung wurde ein Mausmodell gewählt, in dem es nach Administration von Diphterietoxin zur selektiven Depletion CD11c positiver Zellen kommt (C.FVB-Tg(Itgax-DTR/EGFP)57Lan/J). Hierbei wird der Diphterietoxinrezeptor unter dem CD11c Promotor (ITGAX) exprimiert. Aufgrund der Wiederherstellung dendritischer Zellen nach ca. 24 Stunden waren wiederholte Applikationen von Diphterietoxin notwendig. Die Zusammensetzung anderer Immunzellen wurde dabei im Wesentlichen nicht geändert.
Für eine Schlaganfallinduktion wurde eine tMCAO (transient middle cerebral artery occlusion) durchgeführt. Hierbei wird durch Okklusion der A. cerebri media mittels Verschlussfilament für 30 oder 60 Minuten ein Schlaganfall im Mediastromgebiet induziert.
Es wurden unterschiedliche Verschlusszeiten, Zeitpunkte und Depletionsraten untersucht. In keinem der Versuchsansätze kam es zu einer signifikanten Veränderung des Schlaganfallvolumens nach Depletion CD11c positiver Zellen.
Mittels quantitativer real-time PCR wurde die Expression unterschiedlicher Zytokine nach tMCAO und CD11c-Depletion untersucht. An Tag 1 nach Schlaganfallinduktion und hoher Depletionsrate ergab sich eine Verminderung der Expression von IL-1β und IL-6, während an Tag 3 und niedriger Depletionsrate die Expression dieser Zytokine nach CD11c-Depletion zunahm. Grund hierfür könnte die Expression dieser Zytokine durch andere Zellen des Immunsystems, wie etwa neutrophile Granulozyten oder Mikroglia/Makrophagen sein, die möglicherweise einer regulatorischen Funktion durch die Interaktion von Dendritischen Zellen und regulatorischen T-Zellen unterliegen. Weitere experimentelle Ansätze sind notwendig, um diese Fragestellung beantworten zu können.
TGF-β zeigte durchgehend in allen Versuchsanordnungen eine verminderte Expression nach der Depletion dendritischer Zellen. Es ist naheliegend, dass dieses neuroprotektiv-regulatorische Zytokin direkt einer Produktion durch dendritische Zellen oder von nachfolgend aktivierten T-Zellen unterliegt.
In immunhistochemischen Studien konnte des Weiteren keine Änderung des Immigrationsverhaltens von CD11b+ Zellen ins Gehirn gesehen werden.
Diese Studie unterliegt jedoch einigen Limitationen. So stellte sich im Laufe der Experimente heraus, dass die wiederholte Applikation von Diphterietoxin zu einer erhöhten Mortalität der Versuchstiere führte. Nach Fertigstellung der Experimente erschien hierzu eine Publikation, welche die wiederholte Administration von DTX und die Entwicklung einer Myokarditis im gewählten Mausmodell in Zusammenhang brachte.
Die Charcot-Marie-Tooth-Neuropathie umfasst eine heterogene Gruppe von erblichen unter anderem demyelinisierenden Erkrankungen des peripheren Nervensystems. Trotz ihrer hohen Prävalenz von 1:2.500 gibt es bis dato keine kausalen Therapiemöglichkeiten. Durch den progressiven Krankheitsverlauf wird die Lebensqualität der Patienten stetig gemindert; der fortschreitende Verlust der Muskelkraft und Störungen des Gangbildes sind besonders belastend.
Ursächlich für die CMT1-Neuropathie sind unter anderem Mutationen in Genen, die für Moleküle des Myelins von Schwannzellen codieren. Diese Mutationen führen zu einer verminderten Stabilität und Funktion des Myelins und so letzten Endes zu einer Demyelinisierung und axonalen Schädigung der peripheren Nerven. Weitere Studien in CMT1-Mausmodellen zeigten jedoch, dass nicht nur die verringerte Myelinstabilität sondern auch eine durch das Immunsystem vermittelte geringgradige Entzündungsreaktion für die Symptome ursächlich sein könnte. Hier spielen vor allem Makrophagen eine zentrale Rolle. Das Zytokin CSF-1 aktiviert die Makrophagen und verursacht so eine Demyelinisierung der peripheren Nerven. In P0het und Cx32def Mausmodellen konnte nachgewiesen werden, dass eine medikamentöse Inhibition des CSF-1-Rezeptors an Makrophagen zu einem verbesserten Nervphänotypen und einer deutlichen Abmilderung des Krankheitsbildes führte.
In dieser Arbeit wurden in P0het und Cx32def Mausmodellen weiterführende Behandlungsstudien mit einem CSF-1-RI durchgeführt, die untersuchen, zu welchem Zeitpunkt innerhalb des Krankheitsverlaufs (therapeutisch oder präventiv) eine erfolgreiche Therapie noch möglich ist und ob bei einem früheren Beginn eine noch bessere Wirkung erzielt werden kann.
Abhängig von den verschiedenen Start- und Endpunkten waren unterschiedliche Ergebnisse zu beobachten: Hinsichtlich der klinischen Parameter wie der Greifkraft und der Anzahl an abnormal innervierten Synapsen zeigten die Tiere im präventiven Behandlungszweig in beiden Mausmodellen das beste Ergebnis im Vergleich zu den Kontrolltieren. Diese substantielle Verbesserung ließ sich unabhängig von einem Makrophagen-Reflux sogar noch 6 Monate nach Behandlungsabbruch nachweisen.
Bezüglich der endoneuralen Makrophagendepletion war sowohl in den P0het als auch den Cx32def Tieren im präventiven sowie im therapeutischen Behandlungszweig eine signifikante Verbesserung zu beobachten.
Diese Ergebnisse heben ein weiteres Mal die Bedeutung der Makrophagen als Teil einer Entzündungsreaktion in der Pathogenese der CMT1-Neuropathie hervor. Des Weiteren konnte die These gefestigt werden, dass eine Inhibition des CSF-1-Rezeptors zu verbesserten histopathologischen sowie funktionellen Parametern führt. Um ein gutes Ansprechen auf die Therapie zu erzielen, müssen ein möglichst früher Therapiebeginn sowie eine nachhaltige Behandlungsdauer gewährleistet sein.
Background
The role of cytokines in the pathophysiology, diagnosis, and prognosis of small fiber neuropathy (SFN) is incompletely understood. We studied expression profiles of selected pro- and anti-inflammatory cytokines in RNA from white blood cells (WBC) of patients with a medical history and a clinical phenotype suggestive for SFN and compared data with healthy controls.
Methods
We prospectively recruited 52 patients and 21 age- and sex-matched healthy controls. Study participants were characterized in detail and underwent complete neurological examination. Venous blood was drawn for routine and extended laboratory tests, and for WBC isolation. Systemic RNA expression profiles of the pro-inflammatory cytokines interleukin (IL)-1ß, IL-2, IL-8, tumor necrosis factor-alpha (TNF) and the anti-inflammatory cytokines IL-4, IL-10, transforming growth factor beta-1 (TGF) were analyzed. Protein levels of IL-2, IL-8, and TNF were measured in serum of patients and controls. Receiver operating characteristic (ROC)-curve analysis was used to determine the accuracy of IL-2, IL-8, and TNF in differentiating patients and controls. To compare the potential discriminatory efficacy of single versus combined cytokines, equality of different AUCs was tested.
Results
WBC gene expression of IL-2, IL-8, and TNF was higher in patients compared to healthy controls (IL-2: p = 0.02; IL-8: p = 0.009; TNF: p = 0.03) and discriminated between the groups (area under the curve (AUC) ≥ 0.68 for each cytokine) with highest diagnostic accuracy reached by combining the three cytokines (AUC = 0.81, sensitivity = 70%, specificity = 86%). Subgroup analysis revealed the following differences: IL-8 and TNF gene expression levels were higher in female patients compared to female controls (IL-8: p = 0.01; TNF: p = 0.03). The combination of TNF with IL-2 and TNF with IL-2 and IL-8 discriminated best between the study groups. IL-2 was higher expressed in patients with moderate pain compared to those with severe pain (p = 0.02). Patients with acral pain showed higher IL-10 gene expression compared to patients with generalized pain (p = 0.004). We further found a negative correlation between the relative gene expression of IL-2 and current pain intensity (p = 0.02). Serum protein levels of IL-2, IL-8, and TNF did not differ between patients and controls.
Conclusions
We identified higher systemic gene expression of IL-2, IL-8, and TNF in SFN patients than in controls, which may be of potential relevance for diagnostics and patient stratification.
Die Auswirkungen der X-Inaktivierung auf den klinischen Phänotyp bei Patientinnen mit Morbus Fabry
(2023)
M. Fabry ist eine X-chromosomal vererbte Stoffwechselerkrankung. Die Mutation im α-Galactosidase A Gen führt zur reduzierten Aktivität des Enzyms und zur Akkumulation der Stoffwechselprodukte im gesamten Körper. Von der daraus resultierenden Multiorganerkrankung sind sowohl Männer, als auch Frauen betroffen. Als Grund hierfür steht eine verschobene X-Inaktivierung zur Diskussion.
In der vorliegenden Arbeit wurden 104 Frauen rekrutiert und die X-Inaktivierungsmuster in Mundschleimhautepithel, Blut und Hautfibroblasten untersucht. Es wurden umfangreiche klinische und laborchemische Untersuchungen durchgeführt, sodass von jeder Patientin ein klinischer Phänotyp vorlag, der mit Hilfe eines numerischen Scores klassifiziert wurde.
Es zeigte sich, dass Blut ein leicht zu asservierendes Biomaterial mit einer hohen Prävalenz an verschobenen X-Inaktivierungsmustern darstellt. Eine signifikante Korrelation mit dem klinischen Phänotyp konnte in keinem der drei untersuchten Gewebe nachgewiesen werden.
The present cumulative dissertation summarizes three clinical studies, which examine
subgroups of patients within the fibromyalgia syndrome (FMS). FMS entails chronic pain and
associated symptoms, and its pathophysiology is incompletely understood (1). Previous studies
show that there is a subgroup of patients with FMS with objective histological pathology of the
small nerve fibers of the peripheral nervous system (PNS). Another subgroup of FMS patients
does not show any signs of pathological changes of the small nerve fibers. The aim of this
dissertation was to compare FMS patients with healthy controls, and these two FMS subgroups
for differences in the central nervous system (CNS) in order to explore possible interactions
between PNS and the CNS. Regarding the CNS, differences of FMS patients with healthy
controls have already been found in studies with small sample sizes, but no subgroups have yet
been identified. Another aim of this thesis was to test whether the subgroups show a different
response to different classes of pain medication. The methods used in this thesis are structural
and functional magnetic resonance imaging (MRI), magnetic resonance diffusion imaging and
magnetic resonance spectroscopy. For the evaluation of clinical symptoms, we used
standardized questionnaires. The subgroups with and without pathologies of the PNS were
determined by skin biopsies of the right thigh and lower leg based on the intraepidermal nerve
fiber density (IENFD) of the small nerve fibers.
1) In the first MRI study, 43 female patients with the diagnosis of FMS and 40 healthy
control subjects, matched in age and body mass index, were examined with different MRI
sequences. Cortical thickness was investigated by structural T1 imaging, white matter integrity
by diffusion tensor imaging and functional connectivity within neuronal networks by functional
resting state MRI. Compared to the controls, FMS patients had a lower cortical volume in
bilateral frontotemporoparietal regions and the left insula, but a higher cortical volume in the
left pericalcarine cortex. Compared to the subgroup without PNS pathology, the subgroup with
PNS pathology had lower cortical volume in both pericalcarine cortices. Diffusion tensor
imaging revealed an increased fractional anisotropy (FA) of FMS patients in corticospinal
pathways such as the corona radiata, but also in regions of the limbic systems such as the fornix
and cingulum. Subgroup comparison again revealed lower mean FA values of the posterior
thalamic radiation and the posterior limb of the left internal capsule in the subgroup with PNS
pathology. In the functional connectivity analysis FMS patients, compared to controls, showed
a hypoconnectivity between the right median frontal gyrus and the posterior cerebellum and
the right crus cerebellum, respectively. In the subgroup comparisons, the subgroup with PNS
pathology showed a hyperconnectivity between both inferior frontal gyri, the right posterior
parietal cortex and the right angular gyrus. In summary, these results show that differences in
brain morphology and functional connectivity exist between FMS patients with and without
PNS pathology. These differences were not associated with symptom duration or severity and,
in some cases, have not yet been described in the context of FMS. The differences in brain
morphology and connectivity between subgroups could also lead to a differential response to
treatment with centrally acting drugs. Further imaging studies with FMS patients should take
into account this heterogeneity of FMS patient cohorts.
2) Following the results from the first MRI study, drug therapies of FMS patients and
their treatment response were compared between PNS subgroups. As there is no licensed drug
for FMS in Europe, the German S3 guideline recommends amitriptyline, duloxetine and
pregabalin for temporary use. In order to examine the current drug use in FMS patients in
Germany on a cross-sectional basis, 156 patients with FMS were systematically interviewed.
The drugs most frequently used to treat pain in FMS were non-steroidal anti-inflammatory
drugs (NSAIDs) (28.9%), metamizole (15.4%) and amitriptyline (8.8%). Pain relief assessed by
patients on a numerical rating scale from 0-10 averaged 2.2 points for NSAIDs, 2.0 for
metamizole and 1.5 for amitriptyline. Drugs that were discontinued for lack of efficacy and not
for side effects were acetaminophen (100%), flupirtine (91.7%), selective serotonin reuptake
inhibitors (81.8%), NSAIDs (83.7%) and weak opioids (74.1%). Patients were divided into
subgroups with and without PNS pathology as determined by skin biopsies. We found no
differences in drug use and effect between the subgroups. Taken together, these results show
that many FMS patients take medication that is not in accordance with the guidelines. The
reduction of symptoms was best achieved with metamizole and NSAIDs. Further longitudinal
studies on medication in FMS are necessary to obtain clearer treatment recommendations.
3) Derived from previous pharmacological and imaging studies (with smaller case
numbers), there is a hypothesis in the FMS literature that hyperreactivity of the insular cortex
may have an impact on FMS. The hyperreactivity seems to be due to an increased concentration
of the excitatory neurotransmitter glutamate in the insular cortex of FMS patients. The
hypothesis is supported by magnetic resonance spectroscopy studies with small number of
cases, as well as results from pharmacological studies with glutamate-inhibiting medication.
Studies from animal models have also shown that an artificially induced increase in glutamate
in the insular cortex can lead to reduced skin innervation. Therefore, the aim of this study was
to compare glutamate and GABA concentrations in the insular cortex of FMS patients with
those of healthy controls using magnetic resonance imaging. There was no significant
difference of both neurotransmitters between the groups. In addition, there was no correlation
between the neurotransmitter concentrations and the severity of clinical symptoms. There
were also no differences in neurotransmitter concentrations between the subgroups with and
without PNS pathology. In conclusion, our study could not show any evidence of a correlation
of glutamate and GABA concentrations with the symptoms of FMS or the pathogenesis of
subgroups with PNS pathologies.
Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by variants in the gene α-galactosidase A (GLA). As a consequence, the encoded homonymous enzyme GLA is not produced in sufficient amount or does not function properly. Subsequently, globotriaosylceradmide (Gb3), the target substrate of GLA, starts accumulating in several cell types, especially neurons and endothelial cells. FD patients suffer from multiorgan symptoms including cardiomyopathy, nephropathy, stroke, and acral burning pain. It is suggested that the impact of pathological Gb3 accumulation, inflammatory and hypoxic processes, and vasculopathy are contributing to the specific FD pain phenotype. Thus, we investigated the role of inflammation, hypoxia, and vasculopathy on molecular level in dorsal root ganglia (DRG) of the GLA knockout (KO) mouse model. Further, we investigated pain-like characteristics of GLA KO mice at baseline (BS), after capsaicin administration, and after repeated enzyme replacement therapy (ERT) administration for a period of 1.5 years. Acquired data showed disturbances in immune response markers represented by downregulated inflammation-associated genes and lower numbers of CD206+ macrophages in DRG of GLA KO mice. Hypoxic mechanisms were active in DRG of GLA KO mice reflected by increased gene expression of hypoxia- and DNA damage-associated targets, higher numbers of hypoxia-inducible factor 1α-positive (HIF1α+) and carbonic anhydrase 9-positive (CA9+) neurons in DRG of GLA KO mice, and DRG neuronal HIF1α cytosolic-nuclear translocation in GLA KO mice. Vascularization in DRG of GLA KO mice was reduced including lower numbers of blood vessel branches and reduced total blood vessel length. Pain-like behavior of the GLA KO mouse model revealed no mechanical hypersensitivity at BS but age-dependent heat hyposensitivity, which developed also age-matched wild type (WT) mice. Capsaicin administration under isoflurane anesthesia did not elicit the development of nocifensive behavior in GLA KO mice after mechanical or heat stimulation. Repeated ERT administration did not show a clear effect in GLA KO mice in terms of restored heat hyposensitivity to BS paw withdrawal latencies. In summary, we demonstrated the impact of disturbed immune response markers, active hypoxic mechanisms, and reduced vascularization on molecular FD pathophysiology.
Spinal muscular atrophy (SMA) is a disabling disease that affects not only the patient’s health-related quality of life (HRQoL), but also causes a high caregiver burden (CGB). The aim of this study was to evaluate HRQoL, CGB, and their predictors in SMA. In two prospective, cross-sectional, and multi-center studies, SMA patients (n = 39) and SMA patient/caregiver couples (n = 49) filled in the EuroQoL Five Dimension Five Level Scale (EQ-5D-5L) and the Short Form Health Survey 36 (SF-36). Caregivers (CGs) additionally answered the Zarit Burden Interview (ZBI) and the Hospital Anxiety and Depression Scale (HADS). Patients were clustered into two groups with either low or high HRQoL (EQ-5D-5L index value <0.259 or >0.679). The latter group was mostly composed of ambulatory type III patients with higher motor/functional scores. More severely affected patients reported low physical functioning but good mental health and vitality. The CGB (mean ZBI = 22/88) correlated negatively with patients’ motor/functional scores and age. Higher CGB was associated with a lower HRQoL, higher depression and anxiety, and more health impairments of the CGs. We conclude that patient and CG well-being levels interact closely, which highlights the need to consider the health of both parties while evaluating novel treatments.
Die dem Formenkreis der Dystonien zugrundeliegenden, pathophysiologischen Grundlagen sind bislang nicht abschließend geklärt. Für die DYT-TOR1A Dystonie ist bekannt, dass eine 3-bp Deletion eines GAG-Codons im TOR1A-Gen auf Chromosom 9 einen Funktionsverlust des Proteins TorsinA bewirkt. Dieser Funktionsverlust wird als auslösender Faktor für die Entstehung der DYT-TOR1A Dystonie angenommen. Nichtsdestotrotz entwickeln lediglich circa 30% der Mutationsträger eine dystone Bewegungsstörung. Als Grund dafür wird eine Two-hit Hypothese diskutiert, die zusätzlich zur genetischen Prädisposition einen Umweltfaktor wie ein peripheres Trauma für die Entstehung von Symptomen postuliert. Durch eine standardisierte Quetschläsion des N. ischiadicus konnte mit dieser Arbeit bei DYT1KI Mäusen, die die ∆GAG-Mutation im endogenen Genom tragen, ein dystoner Phänotyp hervorgerufen werden. Mit den Aufzeichnungen der Mäuse im TST wurde ein neuronales Netzwerk mittels der Software „DeepLabCut“ trainiert, sodass die Dystonie-ähnlichen Bewegungen automatisiert erfasst und ausgewertet werden konnten. Das Netzwerk trägt dazu bei, dem vorwiegend klinischen Syndrom der Dystonie eine objektive kinematische Charakterisierung zu bieten und kann auf andere TSTs anderer Nagermodelle übertragen werden. Ferner wurde überprüft, ob die beobachteten Bewegungen durch Unterschiede in der Regeneration nach der Nervenquetschung zustande kamen. Elektroneurographien zeigten jedoch diesbezüglich keine Unterschiede zwischen wt und DYT1KI Tieren. Darüber hinaus sind mikromorphologische Prozesse im zentralen und peripheren Nervensystem Gegenstand dieser Studie. Einerseits konnten wir mittels Immunzellfärbungen von T-, B-Zellen, Makrophagen und Mikroglia feststellen, dass sowohl zentral als auch peripher kein Anhalt darauf besteht, dass die beim DYT1KI Mausmodell entstandenen Dystonie-ähnlichen Bewegungen auf einer Dysfunktion oder Aktivierung des Immunsystems, wie es bei anderen neurologischen Erkrankungen bereits nachgewiesen wurde, eine Rolle spielt. Andererseits konnte anhand stereologischer Messungen gezeigt werden, dass bei den naiven DYT1KI Tieren im Vergleich zu wt Tieren dopaminerge Neurone der SN in der Anzahl verringert und im Volumen vergrößert sind, was auf einen Endophänotypen hinweist. Bei den symptomatischen, nervengequetschten DYT1KI Mäusen zeigte sich wiederum eine weitere, signifikante Zunahme der Hypertrophie der dopaminergen Neurone als Hinweis auf eine unmittelbar mit dem dystonen Phänotypen in Zusammenhang stehende Veränderung. Zusammenfassend konnte ein symptomatisches Mausmodell von hoher translationaler Bedeutung etabliert werden, in dem sich Hinweise für eine dopaminerge Dysregulation ergaben und welches für weitere Studien, insbesondere therapeutischer Art, eingesetzt werden könnte.
Now that mechanical thrombectomy has substantially improved outcomes after large-vessel occlusion stroke in up to every second patient, futile reperfusion wherein successful recanalization is not followed by a favorable outcome is moving into focus. Unfortunately, blood-based biomarkers, which identify critical stages of hemodynamically compromised yet reperfused tissue, are lacking. We recently reported that hypoxia induces the expression of endoglin, a TGF-β co-receptor, in human brain endothelium in vitro. Subsequent reoxygenation resulted in shedding. Our cell model suggests that soluble endoglin compromises the brain endothelial barrier function. To evaluate soluble endoglin as a potential biomarker of reperfusion (-injury) we analyzed its concentration in 148 blood samples of patients with acute stroke due to large-vessel occlusion. In line with our in vitro data, systemic soluble endoglin concentrations were significantly higher in patients with successful recanalization, whereas hypoxia alone did not induce local endoglin shedding, as analyzed by intra-arterial samples from hypoxic vasculature. In patients with reperfusion, higher concentrations of soluble endoglin additionally indicated larger infarct volumes at admission. In summary, we give translational evidence that the sequence of hypoxia and subsequent reoxygenation triggers the release of vasoactive soluble endoglin in large-vessel occlusion stroke and can serve as a biomarker for severe ischemia with ensuing recanalization/reperfusion.
Gait disturbances are common manifestations of Parkinson’s disease (PD), with unmet therapeutic needs. Inertial measurement units (IMUs) are capable of monitoring gait, but they lack neurophysiological information that may be crucial for studying gait disturbances in these patients. Here, we present a machine learning approach to approximate IMU angular velocity profiles and subsequently gait events using electromyographic (EMG) channels during overground walking in patients with PD. We recorded six parkinsonian patients while they walked for at least three minutes. Patient-agnostic regression models were trained on temporally embedded EMG time series of different combinations of up to five leg muscles bilaterally (i.e., tibialis anterior, soleus, gastrocnemius medialis, gastrocnemius lateralis, and vastus lateralis). Gait events could be detected with high temporal precision (median displacement of <50 ms), low numbers of missed events (<2%), and next to no false-positive event detections (<0.1%). Swing and stance phases could thus be determined with high fidelity (median F1-score of ~0.9). Interestingly, the best performance was obtained using as few as two EMG probes placed on the left and right vastus lateralis. Our results demonstrate the practical utility of the proposed EMG-based system for gait event prediction, which allows the simultaneous acquisition of an electromyographic signal to be performed. This gait analysis approach has the potential to make additional measurement devices such as IMUs and force plates less essential, thereby reducing financial and preparation overheads and discomfort factors in gait studies.
Ureaplasma species (spp.) are considered commensals of the adult genitourinary tract, but have been associated with chorioamnionitis, preterm birth, and invasive infections in neonates, including meningitis. Data on mechanisms involved in Ureaplasma-driven neuroinflammation are scarce. The present study addressed brain inflammatory responses in preterm lambs exposed to Ureaplasma parvum (UP) in utero. 7 days after intra-amniotic injection of UP (n = 10) or saline (n = 11), lambs were surgically delivered at gestational day 128–129. Expression of inflammatory markers was assessed in different brain regions using qRT-PCR and in cerebrospinal fluid (CSF) by multiplex immunoassay. CSF was analyzed for UP presence using ureB-based real-time PCR, and MRI scans documented cerebral white matter area and cortical folding. Cerebral tissue levels of atypical chemokine receptor (ACKR) 3, caspases 1-like, 2, 7, and C–X–C chemokine receptor (CXCR) 4 mRNA, as well as CSF interleukin-8 protein concentrations were significantly increased in UP-exposed lambs. UP presence in CSF was confirmed in one animal. Cortical folding and white matter area did not differ among groups. The present study confirms a role of caspases and the transmembrane receptors ACKR3 and CXCR4 in Ureaplasma-driven neuroinflammation. Enhanced caspase 1-like, 2, and 7 expression may reflect cell death. Increased ACKR3 and CXCR4 expression has been associated with inflammatory central nervous system (CNS) diseases and impaired blood–brain barrier function. According to these data and previous in vitro findings from our group, we speculate that Ureaplasma-induced caspase and receptor responses affect CNS barrier properties and thus facilitate neuroinflammation.
Background
Eye movement abnormalities are commonplace in neurological disorders. However, unaided eye movement assessments lack granularity. Although videooculography (VOG) improves diagnostic accuracy, resource intensiveness precludes its broad use. To bridge this care gap, we here validate a framework for smartphone video-based nystagmography capitalizing on recent computer vision advances.
Methods
A convolutional neural network was fine-tuned for pupil tracking using > 550 annotated frames: ConVNG. In a cross-sectional approach, slow-phase velocity of optokinetic nystagmus was calculated in 10 subjects using ConVNG and VOG. Equivalence of accuracy and precision was assessed using the “two one-sample t-test” (TOST) and Bayesian interval-null approaches. ConVNG was systematically compared to OpenFace and MediaPipe as computer vision (CV) benchmarks for gaze estimation.
Results
ConVNG tracking accuracy reached 9–15% of an average pupil diameter. In a fully independent clinical video dataset, ConVNG robustly detected pupil keypoints (median prediction confidence 0.85). SPV measurement accuracy was equivalent to VOG (TOST p < 0.017; Bayes factors (BF) > 24). ConVNG, but not MediaPipe, achieved equivalence to VOG in all SPV calculations. Median precision was 0.30°/s for ConVNG, 0.7°/s for MediaPipe and 0.12°/s for VOG. ConVNG precision was significantly higher than MediaPipe in vertical planes, but both algorithms’ precision was inferior to VOG.
Conclusions
ConVNG enables offline smartphone video nystagmography with an accuracy comparable to VOG and significantly higher precision than MediaPipe, a benchmark computer vision application for gaze estimation. This serves as a blueprint for highly accessible tools with potential to accelerate progress toward precise and personalized Medicine.
Low-frequency oscillatory patterns of pallidal local field potentials (LFPs) have been proposed as a physiomarker for dystonia and hold the promise for personalized adaptive deep brain stimulation. Head tremor, a low-frequency involuntary rhythmic movement typical of cervical dystonia, may cause movement artifacts in LFP signals, compromising the reliability of low-frequency oscillations as biomarkers for adaptive neurostimulation. We investigated chronic pallidal LFPs with the Percept\(^{TM}\) PC (Medtronic PLC) device in eight subjects with dystonia (five with head tremors). We applied a multiple regression approach to pallidal LFPs in patients with head tremors using kinematic information measured with an inertial measurement unit (IMU) and an electromyographic signal (EMG). With IMU regression, we found tremor contamination in all subjects, whereas EMG regression identified it in only three out of five. IMU regression was also superior to EMG regression in removing tremor-related artifacts and resulted in a significant power reduction, especially in the theta-alpha band. Pallido-muscular coherence was affected by a head tremor and disappeared after IMU regression. Our results show that the Percept PC can record low-frequency oscillations but also reveal spectral contamination due to movement artifacts. IMU regression can identify such artifact contamination and be a suitable tool for its removal.
Highlights
• Beta-Guided programming is an innovative approach that may streamline the programming process for PD patients with STN DBS.
• While preliminary findings from our study suggest that Beta Titration may potentially mitigate STN overstimulation and enhance symptom control,
• Our results demonstrate that beta-guided programming significantly reduces programming time, suggesting it could be efficiently integrated into routine clinical practice using a commercially available patient programmer.
Background
Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for advanced Parkinson's disease (PD). Clinical outcomes after DBS can be limited by poor programming, which remains a clinically driven, lengthy and iterative process. Electrophysiological recordings in PD patients undergoing STN-DBS have shown an association between STN spectral power in the beta frequency band (beta power) and the severity of clinical symptoms. New commercially-available DBS devices now enable the recording of STN beta oscillations in chronically-implanted PD patients, thereby allowing investigation into the use of beta power as a biomarker for DBS programming.
Objective
To determine the potential advantages of beta-guided DBS programming over clinically and image-guided programming in terms of clinical efficacy and programming time.
Methods
We conducted a randomized, blinded, three-arm, crossover clinical trial in eight Parkinson's patients with STN-DBS who were evaluated three months after DBS surgery. We compared clinical efficacy and time required for each DBS programming paradigm, as well as DBS parameters and total energy delivered between the three strategies (beta-, clinically- and image-guided).
Results
All three programming methods showed similar clinical efficacy, but the time needed for programming was significantly shorter for beta- and image-guided programming compared to clinically-guided programming (p < 0.001).
Conclusion
Beta-guided programming may be a useful and more efficient approach to DBS programming in Parkinson's patients with STN-DBS. It takes significantly less time to program than traditional clinically-based programming, while providing similar symptom control. In addition, it is readily available within the clinical DBS programmer, making it a valuable tool for improving current clinical practice.
Background
Cognitive impairment is a major comorbidity in patients with chronic heart failure (HF) with a wide range of phenotypes. In this study, we aimed to identify and compare different clusters of cognitive deficits.
Methods
The prospective cohort study “Cognition.Matters-HF” recruited 147 chronic HF patients (aged 64.5 ± 10.8 years; 16.2% female) of any etiology. All patients underwent extensive neuropsychological testing. We performed a hierarchical cluster analysis of the cognitive domains, such as intensity of attention, visual/verbal memory, and executive function. Generated clusters were compared exploratively with respect to the results of cardiological, neurological, and neuroradiological examinations without correction for multiple testing.
Results
Dendrogram and the scree plot suggested three distinct cognitive profiles: In the first cluster, 42 patients (28.6%) performed without any deficits in all domains. Exclusively, the intensity of attention deficits was seen in the second cluster, including 55 patients (37.4%). A third cluster with 50 patients (34.0%) was characterized by deficits in all cognitive domains. Age (p = 0.163) and typical clinical markers of chronic HF, such as ejection fraction (p = 0.222), 6-min walking test distance (p = 0.138), NT-proBNP (p = 0.364), and New York Heart Association class (p = 0.868) did not differ between clusters. However, we observed that women (p = 0.012) and patients with previous cardiac valve surgery (p = 0.005) prevailed in the “global deficits” cluster and the “no deficits” group had a lower prevalence of underlying arterial hypertension (p = 0.029). Total brain volume (p = 0.017) was smaller in the global deficit cluster, and serum levels of glial fibrillary acidic protein were increased (p = 0.048).
Conclusion
Apart from cognitively healthy and globally impaired HF patients, we identified a group with deficits only in the intensity of attention. Women and patients with previous cardiac valve surgery are at risk for global cognitive impairment when suffering HF and could benefit from special multimodal treatment addressing the psychosocial condition.
Introduction
IgG4 autoantibodies against paranodal proteins are known to induce acute-onset and often severe sensorimotor autoimmune neuropathies. How autoantibodies reach their antigens at the paranode in spite of the myelin barrier is still unclear.
Methods
We performed in vitro incubation experiments with patient sera on unfixed and unpermeabilized nerve fibers and in vivo intraneural and intrathecal passive transfer of patient IgG to rats, to explore the access of IgG autoantibodies directed against neurofascin-155 and contactin-1 to the paranodes and their pathogenic effect.
Results
We found that in vitro incubation resulted in weak paranodal binding of anti-contactin-1 autoantibodies whereas anti-neurofascin-155 autoantibodies bound to the nodes more than to the paranodes. After short-term intraneural injection, no nodal or paranodal binding was detectable when using anti-neurofascin-155 antibodies. After repeated intrathecal injections, nodal more than paranodal binding could be detected in animals treated with anti-neurofascin-155, accompanied by sensorimotor neuropathy. In contrast, no paranodal binding was visible in rats intrathecally injected with anti-contactin-1 antibodies, and animals remained unaffected.
Conclusion
These data support the notion of different pathogenic mechanisms of anti-neurofascin-155 and anti-contactin-1 autoantibodies and different accessibility of paranodal and nodal structures.
Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
(2023)
Background
Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.
Case presentation
We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.
Conclusion
Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.